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ABSTRACT
Background
Heart failure (HF) is a major health problem affecting 2-3% of the Western population. The clinical 
syndrome of HF is associated with reduced (HFrEF) or preserved (HFpEF) ejection fraction. 
Around 50% of the patients have HFrEF and despite advances in treatment, prognosis remains 
poor and treatments are underutilized. In HFpEF the prognosis is comparable to in HFrEF, but there 
is no evidence-based therapy.
Aims -to investigate
1 The use of evidence-based therapy and survival over time in patients with HFrEF
2 The use of the inotropic drug levosimendan in HF in Sweden
3 a) Contemporary prognosis in patients with severe HFrEF
3 b) If simple predictors of prognosis can be identified and used as criteria for referral to a HF center
4 Predictors of mortality in patients hospitalized with acute decompensated HFpEF  
Evidence-based therapy and survival
We studied 5,908 HFrEF patients with New York Heart Association (NYHA) class II-IV registered 
in the Swedish Heart Failure registry (SwedeHF) between 2003 and 2012. The use of beta-blockers 
and renin angiotensin system (RAS) blockers was >85% and stable over time. There was a decrease 
in the use of mineralocorticoid receptor antagonists (MRA) from 53 to 42%. The use of cardiac 
resynchronization therapy (CRT) and implantable cardioverter defibrillators (ICD) increased over 
time, but absolute numbers were low, less than 11% for both. In 2003 vs. 2012, the 30-day, one-
year, and 3-year survival was 92 vs. 94%, 81 vs. 77% and 58 vs. 54% respectively. The changes in 
survival were not statistically significant. Reported numbers are risk-adjusted.
The use of levosimendan in Sweden
In SwedeHF, 655 registrations were confirmed with use of inotropes. Levosimendan alone was the 
inotropic drug of choice in 91% of the registrations. Of all levosimendan registrations, 38% were 
planned repetitive treatment. The proportion of planned repetitive to all levosimendan registrations 
ranged from 0 to 65% between hospitals.  
Who should be referred to a heart failure center?
We studied 10,062 HFrEF patients with NYHA class III-IV from SwedeHF. One-year survival in 
the age groups ≤65 years, 66-80 years, and >80 years was 90, 79, and 61% respectively. Five pre-
specified risk factors were assessed as potential triggers for referral to a HF center: systolic blood 
pressure ≤90 mmHg; creatinine ≤160 mmol/L; hemoglobin ≤120 g/L; no use of RAS antagonist; 
and no use of beta-blocker. In patients <80 years of age, the presence of 1, 2, or 3-5 of these risk 
factors were associated with a one-year survival of 79, 60, and 39% respectively.
Risk prediction in HFpEF
HF Surveillance data from four different communities in the United States were used to study 
2,304 hospitalizations of HFpEF. Mortality at 28 days and one year was 11 and 34% respectively. 
The most powerful predictors of mortality were higher age, hypoxia, higher blood urea nitrogen 
and lower hemoglobin.
Conclusions
Patients with HF face a high risk of death. In HFpEF novel interventions are urgently called for, 
whereas improving implementation of existing evidence-based treatments should be emphasized 
in HFrEF. Specifically, the poor use of ICD and CRT needs to be recognized. Levosimendan 
was the dominant choice of inotrope in Sweden. Effects of the frequent use of planned repetitive 
levosimendan treatment in a non-acute setting need to be further evaluated. Few and simple risk 
factors used as referral criteria to a HF center, may increase the number of patients who can benefit 
from further therapy. In HFpEF, risk predictors may be used for discrimination of high risk patients 
and contribute to further characterization of this population.
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SAMMANFATTNING
Bakgrund
Omkring 2-3% av den västerländska befolkningen och drygt 200 000 personer i Sverige lever 
med hjärtsvikt (HF). Hjärtsvikt delas in i hjärtsvikt med sänkt (HFrEF) och bevarad (HFpEF) 
ejektionsfraktion. Ungefär hälften av patienterna har HFrEF och trots terapeutiska framgångar 
är prognosen för dessa patienter dålig och tillgänglig behandling underanvänds. Patienter med 
HFpEF har jämförbar prognos med HFrEF, men effektiv behandling saknas. 
Syfte – att studera
1 Användningen av evidensbaserad behandling och överlevnad över tid i HFrEF
2 Användningen av det inotropa läkemedlet levosimendan vid HF i Sverige
3 a) Prognos hos patienter med svår HFrEF
3 b) Om enkla riskprediktorer kan identifieras och användas som kriterier för remittering till ett 
hjärtsviktscenter
4 Mortalitetsprediktorer för patienter inlagda på sjukhus med akut dekompenserad HFpEF
Evidensbaserad behandling och överlevnad
Vi studerade 5 908 patienter med HFrEF och New York Heart Association (NYHA) klass II-IV, 
registrerade i det nationella hjärtsviktsregistret RiksSvikt under 2003-2012. Användningen av 
betablockad och renin-angiotensin-system (RAS) blockad var >85% och stabil över tid medan 
användningen av mineralokortikoid-receptor-antagonist (MRA) minskade signifikant från 53 
till 42%. Implantering av hjärtsviktspacemaker (CRT, cardiac resynchronization therapy) och 
defibrillatorer (ICD, implantable cardioverter defibrillators) ökade över tid, men den absoluta 
användningen var låg, mindre än 11% för båda. Under 2003, jämfört med 2012 var 30-dagars-, 
ett-års- och 3-årsöverlevnaden 92 mot 94%, 81 mot 77% respektive 58 mot 54%. Förändringarna i 
överlevnad var inte statistiskt signifikanta. All rapporterad data är riskjusterad.
Användningen av levosimendan i Sverige
I RiksSvikt studerades 655 registreringar med bekräftad användning av inotropi. Levosimendan 
var det vanligaste inotropa läkemedlet och användes i 91% av registreringarna. Av all 
levosimendananvändning var 38% planerad repetitiv behandling. Andelen planerad repetitiv 
behandling av all levosimendanbehandling varierade mellan 0 och 65% mellan sjukhusen.
Vem bör remitteras till ett hjärtsviktscenter?
Från RiksSvikt studerades 10 062 HFrEF-patienter med NYHA klass III-IV. Ett-års överlevnaden 
i åldersgrupperna ≤65 år, 66-80 år, och >80 år var 90, 79 respektive 61%. Fem predefinierade 
riskfaktorer utvärderades som potentiella kriterier för remiss till ett hjärtsviktscenter: systoliskt 
blodtryck ≤90 mmHg, kreatinin ≥160 µmol/l, hemoglobin ≤120g/l, avsaknad av behandling med 
RAS-blockad och avsaknad av behandling med betablockad. Förekomsten av 1, 2, eller 3-5 risk 
faktorer hos patienter yngre än 80 år gav en ett-års överlevnad på 79, 60 respektive 39%. 
Riskprediktion i HFpEF
Hjärtsviktsbevakningsdata från fyra områden i USA användes för att studera 2 304 
sjukhusinläggningar av patienter med HFpEF. Mortaliteten efter 28 dagar och ett år var 11 
respektive 34%. De viktigaste prediktorerna för död var hög ålder, hypoxi, sänkt njurfunktion och 
lågt hemoglobin. 
Slutsatser
Patienter med hjärtsvikt har hög risk för död. Avseende HFpEF är det angeläget med snar 
utveckling av effektiv behandling. I HFrEF bör däremot befintlig evidensbaserad behandling 
ökas, och specifikt bör underanvändningen av CRT och ICD uppmärksammas. Levosimendan var 
under studieperioden det vanligaste inotropa läkemedlet i Sverige. Emellertid behöver effekten 
av levosimendan som planerad upprepad behandling av kronisk HF studeras bättre. Att använda 
få och enkla riskfaktorer som kriterier för remittering till ett hjärtsviktscenter kan öka andelen 
patienter som får optimal tillgänglig behandling. Riskprediktorer för HFpEF kan användas för att 
identifiera högriskpatienter, vilket bidrar till ytterligare karakterisering av HFpEF-populationen.
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INTRODUCTION
Perspective
In the 1990s the term evidence-based medicine was launched by a group at McMaster 
University, Ontario, Canada1. It was based on a growing recognition of several factors 
including that 1) randomization is the best way to avoid bias and confounding, 2) there are 
variations in treatment practice due to local traditions rather than results from clinical trials 
and, 3) with the fast growing medical literature there is a need to rank evidence according 
to quality (good to poor) to guide clinicians in choices of treatment. In the British Medical 
Journal evidence based medicine was ranked as the 8th most important medical discovery in 
history of any kind, including antibiotics, vaccines, and the discovery of DNA1.
During the last decades there have been dramatic advancements in evidence-based 
interventions for cardiovascular disease. Between 1970 and 2000, life expectancy increased 
by six years, of which more than four were attributed to reduction in cardiovascular mortality 
(Figure 1)2. These gains were mainly in patients with coronary heart disease, but it is 
unknown to what extent they reflect improved care of myocardial infarction as opposed to its 
complications, such as heart failure (HF). Despite advancements in treatment, HF remains 
associated with poor quality of life and is now a leading cause of death and the leading cause 
of hospitalization3.
In this thesis, aspects of evidence-based medicine in HF are studied. To what extent do patient 
receive evidence-based treatments? What are the current traditions for a treatment with poor 
evidence? And finally, where gaps in evidence exist, further description of the disease is 
provided to potentially help targeting future evidence-based treatment. 
Figure 1. Contribution of different conditions to change in life expectancy between 1970 
and 2000 in the USA. 
Reproduced with permission from [Lenfant N Engl J Med. 2003;349(9)], Copyright Massachusetts 
Medical Society.
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General aspects of heart failure
As defined by the European Society of Cardiology (ESC) “heart failure is a clinical syndrome 
characterized by typical symptoms (e.g. breathlessness, ankle swelling and fatigue) that may 
be accompanied by signs (e.g. elevated jugular venous pressure, pulmonary crackles and 
peripheral edema) caused by a structural and/or functional cardiac abnormality, resulting in 
a reduced cardiac output and/ or elevated intracardiac pressures at rest or during stress”4. We 
and other authors emphasize the concept of maintained cardiac output due to neurohormonal 
compensation, which is adaptive in the short run but maladaptive in the long run, leading 
to progressive cardiac remodeling and the signs and symptoms classic for HF (Wallentin, L 
[2010]. Akut kranskärlssjukdom. Liber).
The HF population is broadly characterized by ejection fraction (EF): HF with reduced EF 
(HFrEF) is typically defined as EF <40% and HF with preserved EF (HFpEF) as EF ≥50%.  The 
two entities differ in underlying etiology and comorbidities and in the response to treatment. 
EF between 40-49% represent a grey-zone with some features similar to HFrEF and some 
to HFpEF5. In the latest ESC guidelines for HF from 2016 the term HF with mid-range EF 
(HFmrEF) was introduced for this category4. HFpEF has not been uniformly defined over the 
years, with cut-off values for EF used in trials and observational studies ranging from >40% 
to >55%. In early studies, symptoms of HF in combination with normal EF was typically used 
as diagnosis criteria for HFpEF. In more recent trials, objective evidence of altered cardiac 
structure (e.g. enlarged left atrial volume and/or increased left ventricular mass) and function 
(i.e. abnormal mitral valve inflow patterns and/or mitral annular relaxation velocity) are 
usually required. The latter criteria are in accordance with the diagnosis criteria for HFpEF 
in the latest ESC guidelines4. The term HFpEF is preferred over the earlier used “diastolic 
HF” since despite a normal EF, abnormal systolic chamber structure and myocardial function 
have been shown in these patients6. 
Another way of characterizing HF is to differentiate between chronic stable and acute 
decompensated heart failure (ADHF). ADHF refers to a rapid onset of, or progressive change 
in, symptoms and signs of HF. Patients with ADHF may present with volume overload with 
or without hypoperfusion or with signs of hypoperfusion with or without congestion7. About 
4% of ADHF admissions present with overt cardiogenic shock8.  Hospitalization in HF is 
associated with substantial in-hospital and early post-discharge cardiovascular events9.
Severity of symptoms is often described by the New York Heart Association (NYHA) 
classification (Table 1). Severity of symptoms are related to prognosis10 and in study I-III in 
this thesis, NYHA class is used as a patient selection criterion.
Table 1. New York Heart Association classification
NYHA Symptoms
Class I No limitation of physical activity
Class II Slight limitation of physical activity. Comfortable at rest, but ordinary 
physical activity results in breathlessness and fatigue
Class III Marked limitation of physical activity. Comfortable at rest, but less than 
ordinary physical activity results in breathlessness and fatigue
Class IV Symptoms at rest may be present. Unable to carry out any physical activity 
without discomfort.
Tonje Thorvaldsen
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Epidemiology of heart failure
HF has become a global pandemic with more than 26 million adults suffering from the disease 
worldwide11. The prevalence of HF in the western world is 2-3%12, and is suspected to rise 
as the population grows older to reach a projected 25% increase by 203013. HF is the leading 
cause of hospitalization in patients >65 years of age14. The costs for HF amount to 1-2% of 
all health expenditures in Europe4  and 75% of the costs are related to in-patient care. HF is 
associated with poor quality of life and 5-75% one-year mortality, depending on severity15,16. 
Advanced chronic HF refractory to guideline-based medical HF management affects up to 
5% of the HF population17. Around half of the patients with HF have normal or near-normal 
ejection fraction18, mortality in this group is similar or slightly lower compared to in HFrEF19.
Etiology, risk factors and clinical characteristics
Ischemic heart disease and hypertension are typically seen as the most common causes of 
HF4. Other causes include valvular heart disease, arrhythmias, and cardiomyopathy due to 
e.g. myocarditis, drug and alchohol abuse20. There are several risk factors for the development 
of HF. In the Framingham Heart Study the following variables were associated with an 
increased risk of incident HF (either HFpEF, HFrEF or both): Older age, diabetes mellitus, 
a history of valvular disease, higher body mass index (BMI), smoking, atrial fibrillation, 
male sex, higher total cholesterol, higher heart rate, hypertension, cardiovascular disease, left 
ventricular hypertrophy, and left bundle-branch block (LBBB)21. Both HFrEF and HFpEF 
have high comorbidity burdens, but the HFpEF population tend to have more hypertension, 
atrial fibrillation and chronic kidney disease and less ischemic heart disease22. The patients 
with HFpEF are also more likely to be older and female, and less likely to be African 
American compared to patients with HFrEF23. Furthermore, levels of natriuretic peptides  are 
lower in HFpEF than in HFrEF24.
Prognosticators in heart failure
Numerous predictors of outcome and risk prediction models have been identified and 
developed in HF25. In a systematic review on risk prediction in HF the following factors were 
found to be the most commonly used and strongest predictors of mortality in different risk 
prediction models: Age, renal function, sodium levels, EF, sex, natriuretic peptides, NYHA 
class, diabetes mellitus, BMI and exercise tolerance (measured as peak oxygen consumption)26. 
Prediction of survival in the individual HF patient is complex. Risk prediction models may 
be useful in providing patients and family realistic expectations regarding prognosis, but 
can also be used for patient selection/referral for different therapies. However, many risk 
prediction models are not suitable for daily clinical practice because they are too complex, 
time consuming and often require variables not at hand. The Seattle Heart Failure Model 
(SHFM) and the Heart Failure Survival Score (HFSS) are well validated comprehensive 
risk models used by HF specialists in the evaluation of candidacy for heart transplantation 
(HTx) and mechanical circulatory support (MCS)27,28. For the general practitioner however, 
there are no clear guidelines on when to refer patients for evaluation of advanced HF therapy. 
Therefore, one of the objectives of this thesis was to identify simple clinical parameters that 
can be used as criteria for referral to HF centers. 
Another aspect of risk prediction models is the potential lack of generalizability. Models 
developed from randomized trials may not be applicable to the general population and 
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predictors of mortality in HFrEF may not be the same as in HFpEF.  Prognosticators in 
HFpEF are less studied than in HFrEF. In Study IV in this thesis, we developed a risk 
prediction model for a strict HFpEF population admitted to hospital.
Pathophysiology of heart failure
HFrEF
Myocardial stress or injury in HFrEF is followed by a compensatory neurohormonal (mal)
adaptation to restore/improve hemodynamics. The three main and most studied neurohormonal 
pathways are activation of the 1) sympathetic nervous system 2) renin angiotensin aldosterone 
system (RAAS) and 3) antidiuretic hormone (ADH). In the short term these compensatory 
mechanisms contribute to maintenance of systemic blood pressure (BP) and restoration of 
cardiac output through elevations in cardiac contractility, heart rate, vascular resistance and 
renal sodium and fluid retention. However, in the long term a vicious circle of increased 
afterload, fluid retention and tachycardia results in disease progression, further myocardial 
injury and deterioration of cardiac function. The cardiac structural changes occurring in 
response to the neurohormonal activation is referred to as ventricular remodeling. In HFrEF, 
typical ventricular remodeling is characterized by left ventricular dilatation, increased end-
diastolic volumes and eccentric hypertrophy. A simplified overview of the RAAS is shown 
in Figure 2.
Figure 2. The renin-angiotensin-aldosterone system. 
Adapted from Tomaschitz et al. Nat. Rev. Endocrinol. 2010.6;83-93.
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HFpEF
The pathophysiological pathways of HFpEF are incompletely defined and not as well 
characterized as in HFrEF. Traditionally, the signs and symptoms of HFpEF have been 
attributed to hypertensive left ventricular remodeling including increased left ventricular 
mass, concentric hypertrophy and diastolic dysfunction which in turn leads to development 
of fibrosis and ventricular stiffness29. However, increasing evidence suggest an important 
role of systemic microvascular endothelial inflammation related to comorbidities in HFpEF 
as a cause of fibrosis, increased oxidative stress and alterations in cardiomyocyte signaling 
pathways. These changes may lead to cardiac dysfunction (predominantly diastolic) and 
microvascular dysfunction29-31. Hence, whereas HFrEF is typically triggered by a direct 
cardiomyocyte damage such as myocardial infarction, HFpEF may be more commonly a 
result of comorbidity driven endothelial dysfunction affecting the cardiomyocyte over time 
(Figure 3)30,31.  Neurohormonal activation exists in both HF entities, but it is thought to play 
a less dominant role in HFpEF.
Figure 3. Postulated differences in pathophysiology in HFpEF and HFrEF.
In HFpEF, comorbidities induce a systemic inflammatory state which in turn increases 
oxidative stress in the microvascular endothelium. Myocardial nitric oxid (NO) availability 
decreases affecting signaling pathways in adjacent cardiomyocytes; cyclic guanosine 
monophasphate (cGMP) availability and titin phosphorylation are altered leading to 
concentric remodeling. Transformation of endothelial cells into fibroblasts (EndMT: 
Endothelial mesenchymal transistion) produces fibrosis. In contrast, in HFrEF a direct 
injury on the cardiomyocyte causes cell necrosis, apoptosis and eccentric LV remodeling. 
Reproduced from [Heart, Lam CSP, Lund LH, 102, 257-259, 2016] with permission from BMJ 
Publishing Group Ltd. Original figure from [J Am Coll Card, Paulus, Tschöpe, 62, 263-271, 2013] with 
permission from Elsevier.
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Treatment of HFrEF
Pharmacological treatment
Historically HF was considered a hemodynamic disorder and treatment focused on 
improving hemodynamic parameters32. During the 1980 the understanding of the detrimental 
role of neurohormonal activation in the progression of HF evolved as “the neurohormonal 
hypothesis”, and blocking the sympathetic nervous system and the RAAS became the 
foundation of modern HF treatment. The CONSENSUS and SOLVD trials published in 
1987 and 1991 showed that the angiotensin converting enzyme inhibitor (ACEi) Enalapril 
vs. placebo reduced mortality by 27% and 16% in NYHA class IV and II-III respectively33,34. 
Trials of beta-blockers compared to placebo followed about a decade later (CIBIS II, 
MERIT-HF, COPERNICUS) and showed a mortality reduction of 34-35% in HFrEF35-37. 
For patient intolerant to ACEi, angiotensin receptor blockers (ARB) improve outcomes. 
This was shown in 2003 in the CHARM-Alternative trial,  a randomized controlled trial 
on candesartan in HFrEF38. The treatment with the mineralocorticoid receptor antagonist 
(MRA) Spironolactone, an agent blocking the RAAS by aldosterone antagonism, resulted in 
an incremental mortality reduction of 30% when added to ACEi  in patients in NYHA class 
III-IV (the RALES trial)39. Subsequently,  the EMPHASIS-HF trial from 2011 documented 
that MRAs were effective also in NYHA class II40. In 2014 a new agent was introduced as 
HF treatment; the angiotensin receptor neprilysin inhibitor (ARNI). By inhibiting neprilysin 
the degradation of several endogenous vasoactive peptides including natriuretic peptides, 
bradykinin and adrenomedullin is reduced. ARNI was superior to ACEi in reducing mortality 
in the PARADIGM trial41, and in the ESC HF guidelines of 2016 ARNI are recommended 
as a replacement for ACEi in symptomatic patients4. Notably, neprilysin inhibition enhances 
endogenous compensatory responses, the first time a strategy of enhancing rather than 
inhibiting compensatory responses has been successful.
In search for new HF treatments other approaches to interrupt the RAAS have been studied, 
but with negative or neutral findings. Direct renin inhibition instead of ACEi or added to an 
ACEi did not improve survival 42,43. Studies on the vasopressin receptor antagonists tolvaptan 
were also negative in terms of survival benefit44.
Device therapy
An intraventricular conduction delay (apparent as prolonged QRS-duration on the 
electrocardiogram, ECG),  occurs in 15-30% of patients with HFrEF and often leads to a 
discoordinated ventricular contraction pattern resulting in reduced systolic function and 
increased diastolic volume45. Cardiac resynchronization therapy (CRT) involves pacing the 
left and right ventricle simultaneously, or near simultaneously. By overcoming the electric 
dyssynchrony, CRT induce reverse remodeling with decreased left ventricular volumes. 
Furthermore, CRT reduces mortality by 22%46 in NYHA class III-IV and as more recently 
demonstrated, by 17% in NYHA I-II47 in selected patients with prolonged QRS duration. 
Sudden cardiac death due to ventricular tachyarrhythmia is an important cause of death in 
HFrEF. The use of Implantable cardioverter defibrillator (ICD) as primary prevention of 
sudden cardiac death in ischemic and non-ischemic cardiomyopathy reduces mortality by 25-
30%48-50, although this has more recently been questioned in non-ischemic cardiomyopathy51. 
Landmark trials for ICD treatment are MADIT-II showing survival benefit of ICD in post-
myocardial infarction patients with impaired left ventricular function48 and SCD-HeFT that 
documented survival benefit in ischemic and non-ischemic cardiomyopathies with reduced 
Tonje Thorvaldsen
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EF and NYHA class II-III50. The benefit of ICD when combined with CRT is less certain51,52.
An overview of trials that have contributed to the dramatic advances in the treatment of 
HFrEF is shown in Figure 453.
Advanced therapy: Mechanical assist device and heart transplantation
In severe HF refractory to medical and device therapy, HTx remains the gold standard treatment 
with a one-year survival of almost 90%54. Interestingly, randomized controlled trials have not 
been performed for HTx, yet the overwhelming consensus is that HTx reduces mortality and 
improves quality of life in appropriately selected patients4. However, due to organ shortage, 
artificial heart pumps (left ventricular assist devices, LVADs) have been increasingly utilized 
in these patients. LVADs can be used as 1) a bridge to transplantation (BTT) to maintain end-
organ perfusion and survival while waiting for a HTx, 2) as a bridge to decision (BTD) to 
Figure 4. Trials in HFrEF on pharmacological and device treatment 1986-2014.
Reproduced from [McMurray, Improving outcomes in heart failure: a personal perspective. 
Eur Heart J 2015;36(48):3467-70], by permission of Oxford University Press
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allow time for full clinical evaluation for HTx, 3) as a bridge to candidacy (BTC) to improve 
end-organ function or reverse contraindications in order to become eligible for HTx, and 4) 
as destination therapy (DT) for patients with contraindications for HTx, and 5) in rare cases 
for cardiac recovery facilitated   by LVAD unloading together with intensive neurohormonal 
blockade, leading to reverse remodeling, bridge to recovery (BTR)55.
The landmark trial for LVAD as destination therapy, REMATCH from 2001 showed a relative 
mortality reduction of 48% for patients in NYHA IV with DT LVAD as compared to medical 
therapy56. One- and two-year survival in the study was 52% and 23% respectively. Today 
one-year survival with LVAD is >80%57. Reasons for this remarkable improvement include 
better patient selection and improved surgical techniques and post-operative care. More 
important however, is most likely the advances in LVAD techniques with the introduction 
of continuous flow type pumps58. In 2009 a randomized trial was published comparing the 
new generation of pumps with continuous flow (HeartMate II) with the earlier generation of 
pulsatile flow pumps (HeartMate XVE). A significant increase in survival free from stroke 
and device failure at two years was abserved with the continuous flow device59. Furthermore, 
the latest version of continuous flow pumps with fully magnetically levitated centrifugal-
flow (HeartMate III) was superior to pumps with axial-flow (HeartMate II) with regard to 6 
months outcomes (mainly due to less reoperations for pump malfunctions)60. Very recently, 
in the ENDURANCE trial, the centrifugal-flow LVAD (Heartware) as DT was proved to 
be non-inferior to the axial-flow LVAD (HeartMate II) with regards to survival free from 
disabling stroke and device removal61. However, despite technological improvements, 
LVAD therapy remains associated with a high risk of serious complications including stroke, 
bleeding, pump thrombosis and infections57. 
Advanced therapies with HTx and LVAD therapy are thought to be underutilized17,62. In the 
US, an estimated 100,000 would benefit from HTx62, yet there are only 2,500 performed 
annually54. The main explanation for this is organ shortage63. For LVADs around 25,000–
250,000 patients are estimated to benefit in the US, primarily as DT17, and around 2,500 
LVAD implantations57 are performed annually. The main reason for underutilization of LVAD 
is unknown. A small pilot study identified numerous LVAD candidates through systematic 
screening, suggesting that potential candidates are not recognized in routine clinical care64.
Treatment of HFpEF
In HFpEF, no treatment has yet been convincingly shown to improve outcomes. Treatment 
recommendations are based on expert consensus (not clinical trial results) and include relief 
of volume overload, strategies to improve symptoms and treatment of coexisting conditions. 
Randomized controlled trials of ACEi, ARBs and MRAs have all failed to show improved 
survival in HFpEF65,66. Randomized controlled trials of beta-blockers in HFpEF are small and 
data are conflicting67,68. 
Theories on why trials are negative or neutral include insufficient power, inadequate 
diagnostic criteria for HFpEF and patient heterogeneity. The difficulty of diagnosing HFpEF 
was illustrated in a post-hoc analysis from the TOPCAT trial on spironolactone in HFpEF. 
Regional differences between the Americas and Russia/Georgia was observed both in 
characteristics, event rates and effect of spironolactone and the authors argue that the patients 
from Russia/Georgia were healthier and maybe not “true” HFpEF patients69.
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A randomized trial on ARNI in HFpEF (PARAGON, Clinical Trials.gov number 
NCT01920711) is ongoing. Inclusion criteria are predefined structural changes on Echo, 
elevated natriuretic peptides, HF symptoms and EF ≥45%.
HFpEF is a complex syndrome with a substantial patient and phenotype heterogeneity. One 
theory is that a “one-fits-all” treatment is not effective in HFpEF and that an individualized 
treatment approach based on different patient and etiology phenotypes is necessary70. Hence 
further characterization of HFpEF with regard to pathophysiology and predictors of prognosis 
may be an important step in identifying key areas of potential intervention. In Study IV in 
this thesis we identify predictors of mortality in a HFpEF population hospitalized with ADHF. 
Treatment of ADHF
No treatment has yet been shown to have effect on outcomes in ADHF71. Treatment 
recommendations for ADHF focus on relief of symptoms and treatment of underlying 
disease. In the ESC guidelines for acute HF,  diuretics, vasodilators, inotropic agents and 
vasopressors are recommended for symptom relief, all with a class I or II recommendation 
and level of evidence B or C. Inotropic agents are not recommended unless there are signs of 
hypoperfusion or the patients is symptomatically hypotensive (class III recommendation)4.
Inotropic agents
Intravenous inotropic agents are used to treat acute and in some cases chronic HF with 
concomitant low output, in order to maintain systemic perfusion and preserve end-organ 
function. Conventional inotropes traditionally used are milrinone, dobutamine and dopamine.
Milrinone is a phosphodiesterase inhibitor that increases myocardial calcium concentrations 
and contractility, induces vasodilation and decreases afterload and filling pressures by 
preventing degradation of cyclic adenosine monophosphate (cAMP). 
Dobutamine is a catecholamine that acts mainly on beta1-adrenergic receptors, but also 
imposes minimal effect on beta2- and alpha1- receptors. Hemodynamic effects include 
increased stroke volume and cardiac output with a modest decrease in systemic vascular 
resistance72.
Dopamine is an endogenous catecholamine that in low dose acts on dopamine1-receptors 
dilating various vascular beds including renal and coronary. At intermediate doses dopamine 
stimulates beta1-adrenergic receptors and increases cardiac output by increasing stroke 
volume. At high doses, dopamine acts as an alpha-receptor agonist causing vasoconstriction 
and increased afterload.
The use of these intravenous inotropic agents is deemphasized by American and European 
guidelines because of lack of adequately powered randomized trials and the adverse-event 
risk profile. The adverse impact on outcomes reported include induced myocardial ischemia, 
arrhythmias and increased mortality73-75.
Levosimendan is a relatively novel inotropic agent that was approved in Europe in the 2000s 
for the treatment of advanced acute HF. It is not licensed in the USA. Levosimendan is a 
myofilament calcium sensitizer that stabilizes the interaction between calcium and troponin 
C by binding to troponin C in a calcium dependent manner. Thereby, inotropy is increased 
with no or minimal increase in oxygen demand76. Levosimendan also acts as an adenosine 
triphosphate-dependent potassium channel opener in the sarcolemma of vascular smooth 
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muscle cells and in the mitochondria in cardiomyocytes77. Observed effects of levosimendan 
are increased myocardial contractility, reduction in filling pressures and dilation of arterial, 
venous and coronary vessels78.
The half-life of levosimendan is about one hour and enables fast onset drug action. However, 
the active metabolite of levosimendan, OR-1856, is formed slowly and has a half-life of about 
75 to 80 hours, allowing cardiovascular effects to persist  up to 7-9 days after treatment79.
The early trials LIDO and RUSSLAND suggested that levosimendan improves hemodynamics 
and survival compared to dobutamine and placebo, respectively80,81, but the survival benefit was 
not confirmed in the larger SURVIVE and REVIVE trials82,83. A meta-analysis from 2012 suggests 
an association between use of levosimendan and a reduction in mortality, but larger randomized 
trials sufficiently powered for mortality outcome are currently lacking and called for84.
In clinical practice levosimendan is often used as planned repetitive infusions in severe chronic 
HF. In an expert panel document from 2014 based on 9 studies out of which 6 were randomized, 
the authors concluded that there is evidence of improvements in hemodynamics, symptoms, 
rehospitalization rates and biomarkers with the use of repetitive levosimendan in stable HF, 
regarding survival benefit further studies are needed85. 
Hence, the beneficial effects of levosimendan in acute HF and as planned repetitive treatment 
are uncertain. In Study II in this thesis we aimed to describe the extent of levosimendan 
treatment for these two indications in Sweden. 
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AIMS
The overall aim of this thesis is to describe contemporary patients with HF, with both reduced 
and preserved EF with regards to mortality and markers of poor prognosis, and for HFrEF to 
study patterns of modern treatments and indications for referral to a HF center.  
Specific aims are 
1 To investigate in HFrEF:
	How is implementation of evidence-based treatment over time?
	What is survival over time?
	Is implementation of evidence-based treatment associated with changes in 
survival? (Study I)
2 To assess the use of levosimendan vs. conventional inotropes and the use of 
levosimendan as planned repetitive vs. acute treatment for HF in cardiology and 
internal medicine in Sweden. (Study II)
3 To describe the Swedish country-wide contemporary prognosis in NYHA class III-IV 
HFrEF and to identify simple independent predictors of prognosis that can be used as 
criteria for referral to a HF center. (Study III)
4 To identify predictors of 28-day and one-year mortality in patients hospitalized with 
ADHF and preserved EF and to use these predictors to create risk scores for short and 
intermediate-term mortality at hospital admission. (Study IV)
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PATIENTS AND METHODS
A summary of the data used in this thesis is shown in Table 2.
Data source
Studies I-III 
For Studies I-III, data from the Swedish Heart failure registry (SwedeHF) is used. The 
Swedish heart failure registry (www.swedehf.se) is a nationwide continuous health quality 
and research registry founded in 2000 by Ulf Dahlström, Linköping, Sweden and Magnus 
Edner, Stockholm, Sweden. By 2016 the registry contained more than 70,000 patients from 
Table 2. Overview of the data used in this thesis.
Study I II III IV
Data source SwedeHF SwedeHF SwedeHF ARIC Heart Failure 
Community 
Surveillance
Time of data 
collection
2003-2012 2000-2011 2000-2013 2005-2012
Study 
population
NYHA class II–IV, 
EF <30%   and 
duration of heart 
failure ≥6months
a) Patients with 
confirmed use 
of inotropes              
b) In-patient 
controls: NYHA 
III-IV,  EF <40%
NYHA class III-IV  
EF <40%
Hospitalizations 
with acute 
decompensated 
heart failure and 
EF ≥50%
Design Registry based Registry based Registry based Registry based
Numbers 
in study 
population
5,908 Inotrope use: 655      
in-patient 
controls: 6,069
10,062 2,304        
(weighted sample 
10,789)
Outcomes 1) Implementation 
of evidence-based 
treatment over 
time
2) Survival over 
time
1) Levosimendan 
use in ADHF 
2) Extent 
of planned 
repetitive use of 
levosimendan
One-year mortality 
by number of 
pre-specified risk 
factors
28-day mortality 
and one-year 
mortality from 
hospital admission
Adjustments 38+5 variables None 46 variables 33 variables
Main 
statistical 
analyses
Modified Poisson 
regression with 
adjustment using 
generalized 
estimation 
equations
Descriptive 
comparison 
between groups 
including Kaplan 
Meier survival 
analysis 
Relative survival 
modeling with 
Kaplan-Meier 
analysis
Cox proportional 
hazards regression
Stepwise logistic 
regression
SwedeHF, Swedish Heart Failure Registry; ARIC, Atherosclerosis in the Community; NYHA, New York 
Heart Association; EF, ejection fraction; ADHF, acute decompensated heart failure.
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about 75% of the hospitals in Sweden and about 10% of primary care clinics. Inclusion criteria 
is clinical-judged heart failure and both hospitalizations and out-patient visits are reported 
to the registry. EF is not required, but recorded in around 90%. Patients may be registered 
several times and at an early or late stage in the timeline of their disease. First registration 
does not necessarily mean new-onset HF. Around 80 variables are recorded and entered 
on-line into a database managed by the Uppsala Clinical Research Center. The database 
is run against the Swedish death registry monthly. Informed consent is not necessary, but 
patients are allowed to opt out. The establishment of the registry and all studies receive ethics 
approval. The case report forms are available at www.swedehf.se. 
Coverage has varied somewhat over the years and calculations are complex. In the latest 
annual report from 2015 coverage was 54%, calculated as all unique patients in the registry 
from 2014 with an echo performed, divided by all hospitalized patients in Sweden with a 
primary discharge diagnosis of HF in 2014. Coverage is based on active centers defined as 
hospitals with more than 10 registrations in SwedeHF that year. In primary care coverage is 
much lower.
SwedeHF is financed by the federal government through the Swedish Association of Local 
Authorities and Regions.
Study IV
Study IV is based on data from the Heart Failure Community Surveillance in the 
Atherosclerosis Risk in Communities Study (ARIC). ARIC is a prospective epidemiologic 
study conducted in four U.S. communities (Forsyth County, North Carolina; Jackson, 
Mississippi; suburbs of Minneapolis, Minnesota; and Washington County, Maryland). 
The HF Community Surveillance component of ARIC conducts surveillance of inpatient 
HF in patients aged ≥55 years beginning in 2005 and ongoing. The objectives of the HF 
Surveillance are to monitor long term trends in HF hospitalizations and to provide a platform 
for ancillary studies. 
Eligible hospitalizations are those with a HF related discharge diagnosis in any position 
(International Classification of Disease, Ninth revision, Clinical Modification [ICD-9-CM], 
table 3). The number of cases meeting the eligibility criteria is reduced by applying various 
sampling fractions to different classes of ICD9-CM codes (428 and non-428). The sampling 
fractions or probabilities are defined by age, sex, race and community of residence. This 
procedure is established in order to achieve a balance in the number of events between field 
center, sex, and race groups so that precision of event rates estimates will be similar across 
these strata. 
Abstraction from the medical record is performed by trained personnel. Detailed abstraction 
is performed if there is evidence of symptoms related to HF or physician documentation of 
HF as the reason for hospitalization, otherwise the hospitalization is classified as unlikely and 
no further abstraction is performed.  All hospitalizations are classified by a computer based 
algorithm or physician review, and given an ARIC classification of HF defined as 1) definite 
ADHF, 2) possible ADHF, 3) chronic stable HF, 4) HF unlikely, and 5) HF unclassifiable. If 
there is evidence of increased worsened HF symptoms and intensified HF therapy ADHF is 
selected.
The ARIC Study is carried out as a collaborative study supported by National Heart, Lung 
and Blood Institute.
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Study I
Aim
To investigate in HFrEF:
	 How is implementation of evidence-based treatment over time?
	 What is survival over time?
	 Is implementation of evidence-based treatment associated with changes in survival?
Patients
5,908 unique patients with EF<30%, NYHA class II-IV in SwedeHF between January 2003 
and May 2012 were included in the main analysis.
Protocol
The evidence-based treatment studied were: renin angiotensin system (RAS) antagonists 
(ACEi and or ARB), beta-blockers, MRA, CRT and ICD.
We assessed patient characteristics and crude and risk-adjusted evidence-based treatments 
and survival over time. We adjusted for 38 variables plus the five evidence-based therapies. 
Analysis was performed in a cross-sectional manner, individuals were not followed over time. 
Table 3. Description of eligible international classification of disease (ICD) codes used to 
sample potential Heart Failure hospitalizations in the ARIC HF Surveillance.
ICD-9_CM Disease classification
398.91 Rheumatic heart disease
402.01 Hypertensive heart disease-malignant with congestive heart failure
402.11 Hypertensive heart disease-benign with congestive heart failure
402.91 Unspecified hypertensive heart disease with congestive heart failure
404.01 Hypertensive heart disease and renal failure- malignant with congestive heart failure
404.03
Hypertensive heart disease and renal failure- malignant with congestive heart and 
renal failure
404.11 Hypertensive heart disease and renal failure- benign with congestive heart failure
404.13
Hypertensive heart disease and renal failure- benign with congestive heart and renal 
failure
404.91 Hypertensive heart disease and renal failure- unspecified with congestive heart failure
404.93
Hypertensive heart disease and renal failure- unspecified with congestive heart and 
renal  failure
415.0 Acute cor pulmonale
416.9 Chronic pulmonary heart disease, unspecified
425.4 Other primary cardiomyopathies
428.x Congestive heart failure
518.4 Acure edema of lung, unspecified
786.0x Dyspnea and respiratory abnormalities
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We performed separate sensitivity analyses as follows:
1) Drug dosing defined as percent of target dose for the studied treatments
2) Analysis of the main study population, but with risk-adjustment restricted to those 
variables that changed significantly over time (21 variables)
3) A separate analysis for those centers that participated during the whole study period 
(11 centers)
4) For patients with more than one registration, assessment of changes in therapies 
between first and last visits 
5) Separate analyses for patients seen in cardiology and internal medicine/geriatrics
6) A separate analysis of CRT and ICD use including only centers performing device 
implantation
7) An opportunity-based score measured as the number of treatments divided by the 
number of indicated treatments and an all-or-none score measured as the number of 
patients with all indicated treatments divided by the number of patients eligible for 
all interventions
8) A separate analysis for patients with EF <40% including NYHA I-IV and any 
duration of HF
Endpoints
Endpoints were
1) The use of evidence-based treatment over time. 
2) Survival over time: 
a. One-year and three-year survival post discharge or out-patient visit for the 
whole study population 
b. 30-day survival post discharge for the hospitalized patients
Study II
Aim
To describe the use of levosimendan vs. conventional inotropes and the use of levosimendan 
as planned repetitive vs. acute treatment for HF in cardiology and internal medicine in 
Sweden.
Patients
Patients in SwedeHF between 2000 and 2011 with confirmed inotrope use through validation 
were studied and compared to controls of in-patient registrations with NYHA III-IV and EF 
<40%. 
Protocol
Validation of inotropic treatment: In the early version of the registration case report form 
(CRF) in SwedeHF the variable “received inotropes” was a yes/no variable and indication 
was not recorded. We performed a validation as follows: For centers with ≥ 1 registration 
with “received inotropes” =yes, the local SwedeHF-administrator was asked to control the 
medical history of the patients and complete a CRF on inotropic treatment (Figure 5).
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SwedeHF Validation of treatment with an inotropic agent
1. Personal identification number: ________________________
2. Date of registration: _______________
3. Type of registration:
⁯ Hospitalization
⁯ Out-patient visit
⁯ Visit is not documented in the medical records
4. Administration of an inotropic agent:
⁯ Yes, at the registered visit
⁯ Yes, but at different visit.  Date of administration of the inotropic agent: ____
⁯ No, no administration of an inotropic agent at the registered visit nor at prior visits, go
to item 7
5. Type of inotropic agent: (more than one alternative possible)
⁯ Levosimendan (Simdax) ⁯ Dobutamine (Dobutrex) 
⁯ Milrinone (Corotrop) ⁯ Dopamine (Giludop, Abbodop, Intropin)
⁯ Other inotropic agent _______________
6. Indication for treatment with inotropes. If not clearly stated, check the most 
probable indication. If more than one indication is given, check the main 
indication:
⁯ Peri-operative*, heart surgery ⁯ Peri-operative*, other surgery 
⁯ ACS-STEMI                    ⁯ ACS-NSTEMI
⁯ Pulmonary edema ⁯ Renal failure
⁯ Chock/hypoperfusion ⁯ NYHA IV
⁯ Increased body weight ⁯ Deterioration of heart failure
⁯ Planned treatment** ⁯ Other _____________________
* Peri-operative is defined as administration by an anesthesiologist/in the intensive care 
unit.
**If the patient was admitted for planned treatment, always check this box, even if other 
alternatives are true also.
ACS: acute coronary syndrome, STEMI: ST-elevation myocardial infarction 
NSTEMI: non-ST-elevation myocardial infarction
7. If the answer in item 4 is no, check whether the patient received any of the 
following:
⁯ Cordarone (By mistake taken for an inotropic agent?)
⁯ Digoxine (digoxin has inotropic properties, but is generally not considered inotropic 
medication)
⁯ No documentation of any inotropic agent can be found. Likely a mistake in registration
Figure 5. case report form for validation of levosimendan in SwedeHF.
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For analysis, the indications for inotropic treatment from the CRF were combined to: acute 
coronary syndrome (STEMI and NSTEMI), acute peri-operative (heart and non-heart 
surgery), ADHF (increased body weight, NYHA IV, deterioration HF, chock/hypoperfusion, 
renal failure), unknown, and planned repetitive.
For general comparison of levosimendan treated patients, we selected a control group from 
the registry. Attempting to find patients with similar features as those with inotrope treatment, 
we defined controls as in-patient registrations with NYHA class III-IV and EF <40%.
Individual patients (first registration if more than one) were used for patient characteristics 
and survival analysis. Registrations and not necessarily unique patients were used to assess 
overall levosimendan use and planned repetitive levosimendan use as a proportion of all 
registrations at each center.
We assessed descriptive Kaplan-Meier survival curves for planned repetitive levosimendan, acute 
levosimendan and controls. Because standard criteria for inotrope use such as shock, respiratory 
failure and oliguria, are not captured in the registry, adequate statistical adjustment was not 
feasible and assessment of association between treatment and survival was not performed. For 
patients receiving planned repetitive levosimendan infusions, we assessed potential indications 
for device treatment, HTx and LVAD therapy. Potential indications were defined as follows: the 
respective treatment not already present, and EF<40% and QRS≥120 ms for CRT; EF <40% for 
ICD; EF<40% and age≤65 for HTx, EF <30% and age ≤75 for LVAD- DT.
Endpoints
We performed a descriptive study of the use of levosimendan in Sweden. No statistical 
analysis was undertaken to identify associations between treatment and outcome.
Study III
Aim
To describe the Swedish country-wide contemporary prognosis in NYHA class III-IV HFrEF 
and to identify simple independent predictors of prognosis that can be used as criteria for 
referral to a HF center.
Patients
10,062 unique patients with EF<40% and NYHA class III-IV in SwedeHF between 2000 and 
2013 were analyzed.
Protocol
We divided the study population into three age groups; ≤65, 65-80 and >80 years of age. 
Five simple and universally available risk factors were defined based on 1) previously 
shown properties of poor outcome in HF and 2) availability in daily practice. For descriptive 
purposes the prognostic impact of 12 additional variables were also assessed.
The five predefined risk factors were: systolic BP <90 mmHg, creatinine >160µmol/l, 
hemoglobin ≤120 g/l, no treatment with RAS-antagonist, no treatment with beta-blocker.
Endpoints
Observed and expected all-cause mortality by 3 age-groups
Prognostic impact of 1) the five predefined risk factors independently and 2) the cumulative 
number of the same five risk factors
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Study IV
Aim
To identify predictors of 28-day and one-year mortality in patients hospitalized with ADHF 
and preserved EF and to use these predictors to create risk scores for short and intermediate-
term mortality at hospital admission.
Patients
A total of 2,304 hospitalizations (weighted sample 10,789, accounting for sampling fractions) 
of patients classified as ADHF with an EF ≥50% were included. Patients with a prior reduced 
ejection fraction (“normalized” EF) and EF missing were excluded. Only ADHF at admission 
was included. Further, race other than black or white was excluded due to a very low number. 
Hospitalizations with unknown follow up were also excluded.
Protocol
Thirty-three potential predictor variables were selected based on prior knowledge, clinical 
relevance and availability at the time of presentation.
The derivation sample comprised data from 2005 through 2011. Validation was performed 
in data from 2012.
Based on the prognostic impact of the selected variables in the derivation sample, risk scores 
for 28 days and one year were created. The validation sample was used to validate the risk 
scores.
Endpoints
All-cause mortality at 28 days and at one year from admission date.
Statistics
Statistics in study I-III was performed in R version 2.15.3. Statistics in study IV was 
performed using Stata version 14.1.
The level of significance was set to 5% and all reported p-values and confidence intervals 
are 2-sided.
Unless otherwise stated, continuous variables were expressed as mean (standard deviation) 
and categorical variables as n (%).
Study I
Trends in characteristics over time were assessed with Mantel–Haenszel 𝜒2 test and linear 
regression. Linearity for the continuous variables (including year) was investigated using 
restricted cubic splines and plotting the functional form.
Crude and risk-adjusted use of therapy and survival over time were assessed with regression 
models using generalized estimation equations (GEE). The GEE method may be used when 
individuals within a “cluster” cannot be assumed to be independent with regard to the 
variable of interest. In our study the outcomes may be related within hospitals (cluster). The 
GEE method uses weighted combinations of observations to extract the appropriate amount 
of information from correlated data86. When the probability of an outcome is low (<10%) 
the difference between odds ratios and relative risk is negligible. In our study the utilization 
of therapy and survival were generally expected to exceed 10%. Since risk ratios provide 
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estimates of probability directly, they are more intuitively understood and often preferred to 
odds ratios in epidemiological studies. We therefore estimated rate ratios directly by using 
Zou’s modified Poisson regression and robust variability adjustment with GEE87. Thirty-
eight covariates plus the five evidence-based treatments were included in the risk-adjustment 
model. Risk-adjusted rates are obtained by multiplying the risk ratios from the multivariable 
model by the observed rate from the reference year 2003. Risk-adjusted rates represent 
estimated use of treatment and survival assuming patient characteristics were identical to 
those in 2003.
To avoid bias due to variables missing not at random, we performed multiple imputation 
(using10 imputations).
Study II
Continuous data is shown as median (interquartile range) and n (%). Groups were compared 
using Mann-Whitney U or Fischer’s exact test. Survival was assessed by Kaplan-Meier 
analysis.
Study III
The impact of HF in comparison with expected survival in a comparator population can 
be assessed by relative survival analysis88. Expected survival is defined as the survival 
that would have been observed in the absence of HF. The survival in the Swedish general 
population, matched by age, gender and year of observation was used as expected survival 
(obtained from the Human Mortality database, http://www.mortality.org). Observed and 
expected survival were assessed by Kaplan-Meier analysis. The mortality associated with 
the HF diagnosis can be defined as the “excess mortality” and is measured as the difference 
between the observed and the expected mortality88.
The prognostic impact of the five predefined risk factors was assessed in a multivariable Cox 
proportional hazards regression analysis adjusting for 46 variables. The prognostic impact of 
additional 12 other variables was assessed for descriptive purposes. The proportional hazards 
assumption was tested by scaled Schoenfeld residuals.
The prognostic impact of the cumulative number of risk factors was assessed in a new 
multivariable Cox proportional hazards regression analysis where a new variable was defined 
as “number of risk factors present” and adjustment was performed with 42 variables.
Multiple imputation was performed to avoid bias due to variables missing not at random.
Mortality was assessed with Kaplan-Meier statistics for each of the five risk factors and 
for the cumulative number of the five risk factors. The discrimination of the two regression 
models was assessed by C-index.
Study IV
Patient characteristics were compared between patient dead vs. alive at 28 days and at one 
year by Rao-Scott χ2 test and t-test.
Simple imputation using the sample mean for missing values was performed for variables 
with >5% missing.
The procedure of creating a risk score was performed separately for 28-day and one-year 
mortality. Potential covariates for a risk prediction model were entered in a stepwise forward 
logistic regression. A p-value <0.02 was used as criteria for entering the model. Variables 
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were then removed in a stepwise fashion until discrimination of the model was impacted 
(defined as a reduction in the area under the curve [AUC] by 0.015 from the full model). 
Calibration of the models was performed by Hosmer-Lemeshow statistics.
The coefficients from the logistic regression models (log of the odds ratios) were converted 
into integer points in a risk score and continuous variables were divided into convenient 
intervals. The summation of risk points yields the probability of dying at 28 days and one year 
respectively.  Discrimination of the risk scores was assessed by AUC values and calibration 
by Hosmer-Lemeshow statistics and by plotting observed vs. predicted values.
Validation was performed by assessing discrimination and calibration of the risk scores in 
the validation sample.
Statistical analyses accounted for the stratified sampling design and weighted by the inverse 
of the sampling probability.
Ethical considerations
Study I-III: Establishment of SwedeHF and data analyses from the registry are approved by 
a multisite ethics committee. 
Study IV: Each ARIC Study field center and the coordination ARIC Study center have 
obtained Institutional Review Board approvals.
All studies were conducted in accordance with the declaration of Helsinki.
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RESULTS
Study I
From January 2003 to May 2012, 67 of approximately 75 hospitals and 99 of approximately1000 
primary care out-patient clinics reported to the registry. Of the 74,484 registrations, there 
were 5,908 unique patients with EF <30%, NYHA class II-IV and HF duration ≥6 months.
The number of centers reporting to the registry increased over time from 32 in 2003-2005 to 
104 centers in 2009-2012. Mean age was 72 years and 23% were women. Over all, patient 
characteristics remained stable over time. Significant changes over time included an increase 
in statin use, a decrease in diuretic, nitrate and digoxin use and an increase in the proportion 
of patients with hypertension and NYHA class II. Referral to HF nurse-based clinic and 
hospital-based follow up (as opposed to primary care) also increased significantly over time.
Crude utilization of treatment over time is displayed in Figure 6. Risk-adjusted therapies for 
the main study population and for the sensitivity analysis on 1) patients seen by cardiologists, 
2) patients seen in internal medicine/geriatrics and 3) centers performing device implantation 
(only for the treatments CRT and ICD) are depicted in table 4. In the main study population, 
the risk-adjusted use of RAS antagonists and beta-blockers was >85% with minimal changes 
over time. The use of MRAs decreased significantly from 53 to 42%, risk-adjusted. There 
was a borderline significant increase in the risk-adjusted use of CRT from 2.4 to 8.2% (p 
for trend 0.074). The use of ICDs increased significantly from 4.0 to 10.7%, risk-adjusted. 
The use of device therapy was somewhat higher for patients seen by cardiologist and patient 
treated in hospitals performing device implantation as compared to patients seen in internal 
medicine/geriatrics and to the overall study population. Less than 50% of the patients had 
target doses of RAS antagonists and beta-blockers (Table 5).
Figure 6. Crude use of evidence-based treatment over time.
RAS, renin angiotensin system; MRA, mineralocorticoid receptor antagonists; CRT, cardiac 
resynchronization therapy; ICD implantable cardiac defibrillator
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Crude and risk-adjusted survival over time are shown in Figure 7 and Table 6 respectively. 
There were minimal non-significant changes in risk-adjusted survival; 30-days survival 
increased from 92 to 94%, one-year survival decreased from 81 to 77%, and three-year 
survival decreased from 58 to 54%. For one- and three-year survival somewhat better numbers 
were observed for patients seen by cardiologist (no statistical comparison was performed).
Additional sensitivity analyses
Analysis with adjustment restricted to variables with significant change over time and 
analysis including only the first 11 centers showed similar results as the main analysis apart 
for a higher MRA use in the 11 centers.  When comparing first and last visit, treatment cross-
over was seen in both directions with a 54% increase in beta-blockers for the untreated at first 
visit. MRA treatment was discontinued in 30% and device therapy was added in 11 to 13% 
of the untreated at first visit.
In both the opportunity-based and the all-or-none scores, a significant increase was seen over 
time. For details on these sensitivity analyses we refer to supplementary tables in the original 
article (Supplementary Tables S2-S6 and S12-S13)89.
Table 4. Risk-adjusted evidence-based treatment over time.
Sensitivity analysis I, Patients seen by cardiologist; Sensitivity analysis II, patients seen in internal medicine/
geriatrics; Sensitivity analysis III, hospitals performing device implantation (only for CRT and ICD)
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 RR per year (95% CI)
P for 
trend
RAS-antagonists
Main study population 88.4 91.2 90.2 91.8 89.5 89.2 87.8 89.7 87.9 86.0 0.99 (0.99-1.00) 0.091
Sensitivity analysis I 90.2 91.4 92.0 91.8 90.0 89.5 89.2 90.8 89.6 89.7 1.00 (0.99-1.00) 0.492
Sensitivity analysis II 84.6 92.8 88.1 92.5 90.2 90.8 87.5 89.7 86.2 81.6 0.99 (0.98-1.00) 0.148
Beta-blockers
Main study population 84.8 88.3 89.2 89.0 86.0 89.4 87.8 91.7 90.4 93.4 1.01 (1.00-1.01) 0.008
Sensitivity analysis I 83.5 91.0 89.4 91.9 87.3 91.3 87.8 92.1 90.1 93.4 1.00 (1.00-1.01) 0.079
Sensitivity analysis II 87.5 84.1 88.3 85.6 83.7 86.8 86.7 91.8 91.1 95.4 1.01 (1.01-1.02) 0.001
MRA
Main study population 52.5 53.7 48.5 49.3 47.0 46.4 42.8 41.8 42.9 41.7 0.97 (0.95-0.99) <0.001
Sensitivity analysis I 54.8 61.8 50.2 50.4 46.6 46.5 44.0 41.6 43.5 45.3 0.96 (0.95-0.99) 0.001
Sensitivity analysis II 47.4 44.4 45.2 45.1 44.0 40.8 37.9 39.3 39.9 36.9 0.97 (0.95-1.00) 0.029
CRT
 Main study population 2.4 6.2 3.5 7.0 8.0 6.5 6.0 6.1 7.4 8.2 1.04 (1.00-1.08) 0.074
Sensitivity analysis I 2.4 7.2 3.7 7.8 9.4 7.3 7.4 7.2 8.9 8.6 1.04 (0.99-1.09) 0.100
Sensitivity analysis II 2.5 7.5 6.0 7.3 7.1 7.9 5.1 5.4 6.5 9.4 1.01 (0.94-1.07) 0.861
Sensitivity analysis III 2.7 8.1 4.7 9.8 9.7 8.3 8.4 6.7 9.8 10.0 1.04 (0.98-1.10) 0.249
ICD
 Main study population 4.0 7.0 5.8 4.7 6.8 7.9 6.8 7.2 8.4 10.7 1.07 (1.02-1.11) 0.004
Sensitivity analysis I 4.7 8.7 5.3 4.7 8.5 8.7 8.3 8.1 9.7 13.9 1.08 (1.02-1.14) 0.006
Sensitivity analysis II 2.5 4.9 6.7 4.7 5.0 8.7 5.1 7.1 8.5 6.4 1.06 (0.99-1.13) 0.105
Sensitivity analysis III 5.3 10.1 8.4 6.1 11.5 11.6 12.2 10.6 10.6 12.7 1.05 (0.99-1.10) 0.086
RAS, renin angiotensin system; MRA, mineralocorticoid receptor antagonists; CRT, cardiac 
resynchronization therapy; ICD implantable cardiac defibrillator
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Table 5. Percent of target doses for RAS-antagonists and beta-blockers over time. 
(crude and risk adjusted).
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 RR per year (95% CI)
P for 
trend
Crude
RAS-antagonists (%)
% of target dose 
     ≤50 46.8 50.0 48.4 50.7 46.4 44.0 49.4 50.2 50.4 42.2 1.00 (0.98-1.02) 0.946
     51-99 6.3 7.8 6.9 8.1 7.7 7.4 7.3 7.6 8.6 12.2 1.03 (0.99-1.08) 0.135
    ≥ 100 46.8 42.2 44.7 41.1 45.9 48.6 43.3 42.2 41.0 45.6 0.99 (0.97-1.02) 0.645
Beta-blockers (%)
% of target dose
     ≤50 64.1 70.9 66.1 66.5 62.9 59.7 62.5 63.0 59.4 52.1 0.98 (0.96-0.99) 0.009
     51-99 2.9 6.4 7.5 7.0 8.0 8.0 7.6 6.7 7.7 6.3 1.01 (0.96-1.07) 0.685
    ≥ 100 33.0 22.7 26.4 26.6 29.1 32.3 29.9 30.3 32.9 41.5 1.04 (1.01-1.08) 0.014
Risk-adjusted
RAS-antagonists (%)
% of target dose 
     ≤50 46.8 47.2 44.9 48.6 45.0 42.7 47.5 46.8 46.2 40.6 1.00 (0.98-1.01) 0.647
     51-99 6.3 7.6 7.1 8.2 7.6 7.1 7.1 7.2 8.1 11.2 1.02 (0.97-1.07) 0.390
    ≥ 100 46.8 45.2 48.2 42.7 47.4 50.3 45.0 46.0 44.8 47.9 1.00 (0.98-1.02) 0.925
Beta-blockers (%)
% of target dose
     ≤50 64.1 71.4 65.7 67.0 64.4 60.6 63.4 61.6 59.7 52.2 0.98 (0.96-0.99) 0.001
     51-99 2.9 6.0 7.3 6.5 7.3 7.7 7.6 6.7 7.5 6.2 1.02 (0.96-1.08) 0.538
    ≥ 100 33.0 22.4 27.4 26.7 28.1 31.7 28.7 31.2 32.6 40.8 1.04 (1.01-1.07) 0.006
RAS, renin angiotensin system
Figure 7. Crude survival over time. 
*only for the hospitalized patients, **patients registered 2003-2010
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Study II
The flow of registrations, validation process and selection of controls is shown in Figure 8. 
Inotrope use was confirmed in 655 registrations from 22 centers. In 618 of those, levosimendan 
was used (including 21 registrations with both levosimendan and conventional inotropes). Of 
all levosimendan registrations, 38% were planned repetitive treatment. We identified 4,418 
inpatient controls in NYHA III-IV and EF<40%. Of registrations with confirmed levosimendan 
use, 2 were out-patient visits and 97 had either NYHA class I-II or EF ≥40% (in contrast to 
the controls). Selected numbers and percentages on registrations and reporting centers are 
shown in table 7 and indications for levosimendan treatment are depicted in Table 8. Patients 
who received planned repetitive levosimendan treatment (as opposed to acute treatment and 
controls) were younger, more commonly male, and more frequently treated in cardiology. 
They had better renal function and they had more evidence-based treatments (table 9). One-
year survival was 81% for patients with planned repetitive levosimendan, 62% for patients 
with acute levosimendan and 66% for the controls, the survival curves are shown in Figure 
9. Proportions of levosimendan treatment to total registrations and patients are shown in 
Figure 10. The proportion of treatment to total registrations ranged between 1 and 52% and 
the proportion of planned repetitive to total levosimendan registrations ranged between 
0 and 65%.  Of the 87 patients who received planned repetitive levosimendan, existing 
interventions were: CRT 41%, ICD 41%, HTx 1% and LVAD unknown (assumed 0%). 
Potential interventions among the remaining, not already treated were: CRT: 46%, ICD 98%, 
Htx 49% and LVAD 58%.
Table 6. Risk-adjusted survival over time. 
Sensitivity analysis I, Patients seen by cardiologist; Sensitivity analysis II, patients seen in internal 
medicine/geriatrics. *only for the hospitalized patients, **patients registered 2003-2010
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 RR per year (95% CI)
P for 
trend
30-day survival*
Main study population 91.8 93.7 93.7 92.6 90.0 90.9 89.4 92.4 91.4 93.6 1.00 (0.99-1.00) 0.532
Sensitivity analysis I 88.6 92.2 95.8 94.6 89.8 90.3 88.0 89.4 89.1 90.9 0.99 (0.99-1.00) 0.033
Sensitivity analysis II 100.0 93.2 91.2 88.7 85.4 88.2 88.9 96.6 92.4 95.1 1.00 (1.00-1.01) 0.306
1-year survival
Main study population 80.8 77.5 79.3 75.3 75.2 75.6 75.9 76.1 75.2 76.9 1.00 (0.99-1.00) 0.260
Sensitivity analysis I 83.5 80.8 78.9 80.9 75.0 77.2 75.3 74.5 77.1 75.7 0.99(0.99-1.00) 0.006
Sensitivity analysis II 75.0 70.7 75.8 65.3 71.2 69.7 73.0 73.4 69.4 75.2 1.00(0.99-1.02) 0.676
3-year survival**
Main study population 57.6 55.7 57.1 56.2 56.3 53.2 56.7 54.3 - - 0.99 (0.98-1.01) 0.425
Sensitivity analysis I 60.0 59.3 62.9 60.6 57.5 56.1 58.2 54.4 -- -- 0.99(0.97-1.00) 0.067
Sensitivity analysis II 52.5 45.8 45.6 44.1 49.1 45.4 48.8 46.6 -- -- 1.01(0.98-1.03) 0.623
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Table 7. Selected numbers and percentages 
*Control registrations were in-patients
Number n Percentages %
Registrations with ”received inotropes” = yes 1344 Percent of total registrations 2.5
Hospitals reporting ”received inotropes” = yes 54 Percent of total reporting  hospitals 86
Hospitals responding and validating individual 
patient inotrope use
22 Percent of total reporting hospitals 35
Hospitals of these 22 that validated 
levosimendan use
21 Percent of total reporting hospitals 33
Iv inotropes use and agent confirmed at the 
relevant hospitalization
655 Percent of all in-patients with NYHA III-IV 
and EF <40%*
10
Levosimendan registrations 597 Percent of inotrope registrations 91
Acute levosimendan registrations 384 Percent of acute inotrope registrations
Planned repetitive levosimendan registrations 234 Percent of levosimendan registrations 38
Planned repetitive levosimendan patients 87 Inotrope patients + controls 1.8
Planned repetitive levosimendan patients 87 Levosimendan patents 22
NYHA III-IV and EF <40%. NYHA, New York Heart Association; EF, ejection fraction
Figure 8. Flowchart of registrations, validation and individual patients. 
NYHA, New York Heart Association; EF, ejection fraction
57,965 Registrations
4,417 Registrations
Inotrope therapy missing 
53,548
Inotropes yes: 1,344 Inotropes no: 52,204
Validation request:
No response: 376
Validation: i.v. 
inotropes on this date 
not confirmed: 689
I.v. inotrope treatment 
and agent confirmed: 
655 registrations
Out-patient; 21,197
Not NYHA III-IV and 
EF<40%: 24,938
Controls:
6,069
registrations
Levosimendan: 597 Both: 21 Conventional: 37
Levosimendan: 618
Planned 
repetitive: 234 
registrations
Acute:
384 
registrations
4,418 individual 
patients
87 individual 
patients
306 individual 
patients
Total
Registrations:
6,687
Patients:
4,811
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Table 8. Levosimendan indications.
Indication for levosimendan use Registrations n (%)
Planned repetitive registrations 234 (38)
Acute 
•	 Acute decompensated heart failure 331 (54)
•	 Acute coronary syndrom 42 (7)
•	 Peri-operative 3 (0.5)
•	 Unknown indication 8 (1)
Table 9. Patient characteristics.
Variable % 
missing
Planned 
repetitive 
levosimendan
n=87 patients 
(1.8%)
Acute 
levosimendan
n=306 patients
(6.4%)
No inotropes 
(controls)
n=4418
patients
(92%)
P 
planned 
vs.
acute
P 
planned 
vs. 
control
P
acute
vs. 
control
Follow-up time, days 0
627 
(217-966)
372 
(90-765)
494
 (144-1008)
Number of dead 0 30 (34%) 152 (50%) 2419 (55%)
Demographics
Age, years 0 64 (56-74) 69 (58-76) 78 (69-84) 0.074 <0.001 <0.001
Gender, male 0 79 (91%) 253 (83%) 3082 (70%) 0.067 <0.001 <0.001
Married / co-habitating 5 67 (79%) 178 (60%) 2293 (55%) 0.001 <0.001 0.091
Independent living 10 80 (100%) 253 (97%) 3694 (92%) 0.123 0.002 0.007
Cardiology specialty 0 82 (94%) 262 (86%) 2520 (57%) 0.041 <0.001 <0.001
Specialty follow-up 15 81 (98%) 220 (81%) 2064 (55%) <0.001 <0.001 <0.001
Clinical
NYHA at discharge 1 0.035 <0.001 <0.001
      I 4 (5%) 5 (2%) 0 (0%)
      II 16 (21%) 37 (15%) 0 (0%)
      III 46 (61%) 141 (57%) 3717 (84%)
      IV 10 (13%) 65 (26%) 701 (16%)
EF, % 0 0.078 <0.001 <0.001
      ≥ 50 0 (0%) 12 (4%) 0 (0%)
      40-49 3 (4%) 20 (7%) 0 (0%)
      30-39 20 (24%) 48 (16%) 1719 (39%)
       < 30 60 (72%) 219 (73%) 2699 (61%)
Systolic blood pressure, mm Hg 1 105 (95-118) 107 (95-120) 120 (105-130) 0.911 <0.001 <0.001
Diastolic blood pressure, mm Hg 1 70 (60-70) 65 (60-72) 70 (60-80) 0.893 <0.001 <0.001
Heart rate, beats per minute 9 70 (68-77) 77 (70-90) 75 (67-86) <0.001 0.019 0.002
Chest x-ray confirmed congestion 19 13 (24%) 116 (50%) 1953 (54%) <0.001 <0.001 0.175
QRS ≥ 120 ms* 39 11 (46%) 64 (40%) 1235 (45%)
Laboratory
Creatinine clearance, ml/min 5 68 (46-91) 57 (39-89) 48 (33-70) 0.056 <0.001 <0.001
Hemoglobin, g/L 0 130 (116-142) 125 (114-139) 129 (117-142) 0.161 0.904 0.005
NT-pro-BNP, pg/mL 76
3839 
(924-7650)
6830 
(3130-15408)
6280 
(3126-12866)
0.001 0.001 0.459
Medical history
Hypertension 4 27 (32%) 101 (34%) 1909 (45%) 0.697 0.020 0.001
Diabetes mellitus 1 29 (33%) 98 (32%) 1361 (31%) 0.897 0.641 0.654
Ischemic heart disease 3 50 (57%) 179 (60%) 2632 (61%) 0.712 0.505 0.540
Atrial fibrillation/ flutter 1 45 (52%) 143 (47%) 2179 (50%) 0.466 0.746 0.344
Lung disease 3 11 (13%) 60 (20%) 852 (20%) 0.155 0.131 0.940
Tonje Thorvaldsen
36
Table 9. Patient characteristics.
Variable % 
missing
Planned 
repetitive 
levosimendan
n=87 patients 
(1.8%)
Acute 
levosimendan
n=306 patients
(6.4%)
No inotropes 
(controls)
n=4418
patients
(92%)
P 
planned 
vs.
acute
P 
planned 
vs. 
control
P
acute
vs. 
control
Medications
ACE-inhibitor and/or ARB 2 80 (93%) 247 (82%) 3565 (82%) 0.011 0.009 0.755
B-blocker 0 83 (95%) 266 (87%) 3878 (88%) 0.032 0.029 0.649
MRA 0 58 (67%) 172 (57%) 1745 (40%) 0.108 <0.001 <0.001
Digoxin 0 26 (30%) 71 (23%) 885 (20%) 0.208 0.030 0.185
Diuretic 0 82 (94%) 281 (92%) 4067 (92%) 0.647 0.684 0.826
Oral anticoagulant 0 58 (67%) 162 (53%) 1623 (37%) 0.028 <0.001 <0.001
Existing alternative treatments
CRT 1 35 (41%) 62 (20%) 248 (6%) <0.001 <0.001 <0.001
ICD 1 35 (41%) 53 (17%) 232 (5%) <0.001 <0.001 <0.001
Heart transplant 9 1 (1%) 1 (0%) 5 (0%) 0.416 0.111 0.313
LVAD NA NA NA NA NA NA NA
Alternative treatment candidates#
CRT candidate 40 11 (46%) 59 (37%) 1224 (45%) 0.501 1.000 0.058
ICD candidate 8 48 (98%) 218 (88%) 4154 (100%) 0.038 0.012 <0.001
Heart transplant candidate 10 37 (49%) 101 (40%) 718 (18%) 0.183 <0.001 <0.001
LVAD candidate 0 48 (58%) 171 (57%) 1256 (28%) 1.000 <0.001 <0.001
Data are median (interquartile range) or n (%)
p is by Mann-Whitney U or Fischer’s exact test
*QRS width is assessed only in patients without pacemaker, CRT or ICD.
#Candidacy for alternative treatment was assessed on planned repetitive patients only and is explained in the text.
ACE-inhibitor, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CRT, cardiac 
resynchronization therapy; EF, ejection fraction; ICD, implantable cardioverter defibrillator; LVAD, left ventricular 
assist device; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-brain natriuretic peptide; 
NYHA, New York Heart Association; NA, not applicable; 
LVAD patients are cared for in surgical departments and not reported to the Registry and are rare in Sweden.
Figure 9. Crude descriptive survival by Kaplan-Meier analysis. No association between 
treatment and outcome is assessed.
          Heart failure: Studies of prognosis and advanced therapy
37
Study III
Patient selection is depicted in Figure 11. Included in the main analysis were 10,062 unique 
patients with EF <40% and NYHA class III-IV from SwedeHF between 2000 and 2013. 
The number of patients in age groups were as follows: 2,247 age ≤65 years, 4,632 age 66 to 
80 years and 3,183 age >80 years. Younger patients were generally healthier and had more 
evidence-based treatment, they had lower EF and were more commonly male.
Overall one-year and five-year survival, observed vs. expected were 76 and 39% vs. 95 and 
76% (Figure 12A). By age groups, the corresponding numbers were as follows: age ≤65 
years, 90 and 68% observed vs. 99 and 96% expected (Figure 12B); age 66 to 80 years, 79 
Figure 10. Use of levosimendan by individual hospitals: a) Number of levosimendan 
registrations (black) as a proportion of total registrations, b) Number of levosimendan 
individual patients (black) as a proportion of total individual patients, c) Number of planned 
repetitive levosimendan registrations (black) as a proportion of total levosimendan 
registrations, d) Number of planned repetitive levosimendan individual patients (black) as 
a proportion of total levosimendan individual patients
A B
C D
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and 40% observed vs. 97 and 83% expected (Figure 12C); and age >80 years, 61 and 17% 
observed vs. 89 and 52% expected (Figure 12D). The relative difference between excess 
mortality and actual mortality was higher in the age groups up to 80 years compared to >80 
years.
The predefined risk factors were all independent predictors of mortality (Table 10 and 
Figure 13). Figure 12 displays the hazard ratios for the five risk factors and the additional 
12 selected variables. Survival by number of the five risk factors is shown in Figure 14a and 
Table 10. The presence of one risk factor was associated with a one-year survival of 79%. 
For comparison, one-year survival for HTx is around 90% and LVAD around 80%. Survival 
decreased progressively by number of risk factors. A separate analysis on NYHA class II 
is shown in Table 11 and Figure 14b. The survival by risk factors was higher compared to 
NYHA III-IV.
The c-index for the 5-risk factor-model was 0.71, and the c-index for the one-variable-model 
on cumulative number of risk factors was 0.73.
 
Figure 11. Patient selection.
85,291 registrations
11 May 2000 to 5 June 2013
43,477 EF < 40%
2,760 NYHA I
9,053 NYHA unknown
31,664 EF < 40% and NYHA II-IV
30,947 EF ≥ 40%
10,867 EF unknown
2,247 age ≤ 65
141 registered after last run against 
death registry or unknown registration 
dates or identification number
31,523
11,998 repeat registrations
19,525 unique patients
EF < 40% and NYHA II-IV
Descriptive statistics and excess mortality 
Assessment of independent risk factors
and mortality according to risk factors
Excluded from 
risk factor 
analysis
10,062 NYHA III-IV main analysis 9,463 NYHA II extended analysis
4,632 age 66-80 3,183 age > 80 3,226 age ≤ 65
Assessment of independent risk factors
and mortality according to risk factors
Excluded from 
risk factor 
analysis
4,346 age 66-80 1,891 age > 80
Descriptive statistics 
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Table 10. Survival by a) each of the 5 risk factors and b) the cumulative number of risk 
factors. Patient <80 years, NYHA class III-IV
A. Risk factor*
Reference level for HR
n dead / n total 1-year survival HR 95% CI p-value
Systolic BP ≤ 90 mm Hg
Systolic BP > 90 mm Hg
304/520
2673/6359
68%
84%
1.64 1.43-1.88 <0.001
Creatinine ≥ 160 µmol/L
Creatinine <  160 µmol/L
611/827
2366/6052
58%
86%
1.91 1.72-2.12 <0.001
Hemoglobin ≤ 120 g/L
Hemoglobin > 120 g/L
929/1568
2048/5311
69%
86%
1.32 1.21-1.43 < 0.001
Not treated with RAS-antagonist
Treated with RAS-antagonist
401/559
2576/6320
58%
85%
1.56 1.39-1.75 <0.001
Not treated with β-blocker
Treated with β-blocker
352/587
2625/6292
71%
84%
1.28 1.14-1.44 <0.001
B. Number of risk factors† n dead / n total 1-year survival HR‡ 95% CI p-value
      0 1262/3905 90%
      1 944/1870 79% 1.40 1.28-1.53 <0.001
      2 488/672 60% 2.30 2.05-2.57 <0.001
      3-5 186/221 39% 4.07 3.44-4.82 <0.001
 NYHA, New York Heart Association; HR, hazard ratio; BP, blood pressure; RAS renin angiotensin system
Figure 12. Observed and expected all-cause mortality, NYHA class III-IV
a) overall, b) age ≤65 years, c) 66-80 years, d) >80 years.
NYHA, New York Heart Association
A B
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Table 11. Survival by a) each of the 5 risk factors and b) the cumulative number of risk 
factors. Patient <80 years, NYHA class II
A. Risk factor*
Reference level for HR
n dead / n total 1-year survival HR 95% CI p-value
Systolic BP ≤ 90 mm Hg
Systolic BP > 90 mm Hg
69/268
1630/7304
91%
94%
1.10 0.85-1.43 0.477
Creatinine ≥ 160 µmol/L
Creatinine <  160 µmol/L
183/354
1516/7218
79%
95%
1.74 1.46-2.07 <0.001
Hemoglobin ≤ 120 g/L
Hemoglobin > 120 g/L
385/1043
1314/6529
87%
95%
1.37 1.21-1.55 < 0.001
Not treated with RAS-antagonist
Treated with RAS-antagonist
126/293
1573/7279
84%
94%
1.28 1.05-1.55 0.014
Not treated with β-blocker
Treated with β-blocker
138/487
1561/7085
93%
94%
1.16 0.97-1.39 0.113
B. Number of risk factors† n dead / n total 1-year survival HR‡ 95% CI p-value
      0 1005/5457 96%
      1 474/1566 91% 1.36 1.21-1.53 <0.001
      2 142/317 84% 1.81 1.50-2.18 <0.001
      3-5 37/57 66% 2.64 1.84-3.77 <0.001
NYHA, New York Heart Association; HR, hazard ratio; BP, blood pressure; RAS renin angiotensin system
Figure 13.  All cause mortality: Hazard ratios  and 95% confidence intervals for the 5 main 
and 12 additional risk factors.
NYHA, New York Heart Association; EF, ejection fraction; BMI, body mass index; NT-proBNP, n-terminal 
probrain natriuretic peptide; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor 
blocker; MRA, mineralocorticoid receptor antagonist; CRT, cardiac resynchronization therapy; ICD, 
implantable cardioverter defibrillator.
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Study IV
Figure 15 illustrates the selection process of the HFpEF hospitalizations in the ARIC 
Surveillance. A sample of 2,304 (weighted sample of 10,789) hospitalizations were included 
for analysis. Overall, mean (standard error) age was 77 (0.27), 74% were white and 35% were 
male. Sixty-five percent had a prior diagnosis of HF and 29% had a prior hospitalization for 
HF. Twenty-eight-day and one-year mortality was 11 and 34% respectively. Those who died 
were older and more likely to be white. They were also more likely to be underweight and 
have a history of atrial fibrillation/flutter, anemia, pulmonary hypertension and valvular heart 
disease. Furthermore, those who died had higher levels of natriuretic peptides and blood urea 
nitrogen (BUN), lower levels of hemoglobin, and their BP at admission was lower. 
 Nine and 8 predictors of 28-day and one-year mortality respectively were identified (Figure 
16a and b). The most powerful predictors in both models were higher patient age, higher 
BUN, hypoxia and lower hemoglobin levels. Discrimination measured by AUC was 0.774 
and 0.724 for 28-day and one-year mortality respectively. Calibration was good, with non-
significant Hosmer-Lemeshow p-values in both models.
The risk scores are shown in Table 12. The predicted mortality at 28 days and one year using 
the risk scores was 10 and 33% respectively yielding observed to predicted ratios of 1.10 
and 1.03. The AUC for the short- and intermediate-term risk scores were 0.768 and 0.718 
respectively.  The distribution of the risk scores and association with mortality is shown in 
Figure 17 and calibrations plots are shown in Figure 18.
In the validation sample, 28-day and one-year mortality was 8 and 33% respectively. 
Distribution of the risk scores in the validation sample are shown in Figure 19. Discrimination 
in the validation sample was somewhat weaker than in the derivation sample. AUC was 
0.700 and 0.692 for 28-day and one-year mortality respectively. Calibration was good as 
shown in Figure 20.
Figure 14. Survival rates by number of risk factors, age <80 years a) NYHA III-IV, b) NYHA II
For comparison, dotted lines represent the approximate one-year survival for heart 
transplantation (90%) and left ventricular device (80%). The 5 risk factors were systolic 
blood pressure <90 mmHg, creatinine >160µmol/l, hemoglobin ≤120 g/l, no treatment 
with renin angiotensin system antagonist, no treatment with beta-blocker.
A B
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Figure 15. Selection of hospitalizations of HFpEF.
ICD, international classification of disease, ADHF, acute decompensated heart failure; ARIC, 
atherosclerosis risk in the commuity; EF,ejection fraction.
ADHF developed during hospitalization n=206
Eligible hospitalizations based on ICD codes 
2005-2012  n=18,365
ADHF (definite or probable 
by ARIC definition) n=7,101
ADHF unlikely or unclassifiable n=11,264
ADHF  HFPEF n=2,649
Current EF <50% n=3,637
Prior EF <50% n=178
EF missing n=637
ADHF  HFPEF n=2,422
Races other than black and white n=21
ADHF  HFPEF  n=2,304 (accounting for sampling fractions n=10,789)
Derivation sample (year 2005-2011): 1,852 
Validation sample (year 2012): 452
Unknown follow up status n=118
A
B
Figure 16. Predictors of a) 28-day and b) one-year mortality.
BUN, blood urea nitrogen; BMI, body mass index; SD, standard deviation
Hypoxia defined as documented saturation <90% or  the word “hypoxia” stated in the medical records.
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Table 12. Risk score
Predictor Points  28-day mortality Max score
Age <70 70-80 ≥80
 +0 +6 +10 +10
BUN (mg/dL) <30 30-70 70-110 ≥110
 +0 +1 +8 +16 +16
Hemoglobin (g/dL) >13 11-13 9-11 <9
 +0 +4 +7 +10 +10
Heart rate (bpm) <70 70-90 90-110 110
 +0 +3 +5 +8 +8
Natriuretic peptides
   BNP(pg/mL) <196 196-1,642 ≥1,642
   NT-proBNP age<75 (pg/mL) <885 885-12,161 ≥12,161
   NT-proBNP age>75 (pg/mL) <1372 1372-13,884 ≥13,884
 +0 +6 +13 +13
Diastolic BP (mmHg) ≥100 70-100 <70
 +0 +6 +12 +12
Hypoxia +7 +7
White race +7 +7
BMI <18.5 (kg/m2) +13 +13
Highest possible score 91
 Points  one-year mortality
Age <70 70-80 ≥80
 +0 +4 +8 +8
Hemoglobin (g/dL) >13 11-13 9-11 <9
 +0 +1 +6 +10 +10
BUN (mg/dL) <30 30-70 70-110 ≥110
 +0 +2 +7 +10 +10
Systolic BP (mmHg) ≥150 130-150 110-130 110
 +0 +3 +5 +6 +6
Heart rate (bpm) <70 70-90 90-110 >110
 +0 +4 +6 +7 +7
Hypoxia +6 +6
BMI <18.5 (kg/m2) +15 +15
Atrial fibrillation/flutter +4 +4
Highest possible score 66
BUN, blood urea nitrogen; BNP, brain natriuretic peptide; NT-proBNP, N-terminal pro-brain natriuretic peptide; BP, 
blood pressure; BMI, body mass index; 
Figure 17. Distribution of risk score for a) 28-day and b) one-year mortality and the 
association with predicted mortality.
A B
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Figure 18. Observed vs. predicted mortality by deciles of risk score for a) 28-day and b) 
for one-year mortality
Figure 19. Validation: Distribution of risk score for a) 28-day and b) one-year mortality 
and the association with predicted mortality
Figure 20. Validation: Observed vs. predicted mortality by deciles of risk score for a) 28-
day and b) for one-year mortality
A B
A B
A B
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GENERAL  DISCUSSION
Despite advancement in therapy for HFrEF, mortality remains high and the utilization 
of available treatment is unclear. HFpEF is still an unsolved dilemma with substantial 
uncertainties regarding disease phenotypes, prognosticators and treatment.
The first studies in the present thesis focus on contemporary prognosis, current treatment 
patterns and indications for referral for advanced therapy in HFrEF. (Study I-III). In the last 
part of the thesis mortality and prognosticators of HFpEF are studied (Study IV).
Survival in heart failure
Substantial improvement in HF survival has been described before the turn of the millennium. 
In the Framingham study mortality improved by 12% per decade between 1950 and 2000 to 
about 10% at 30 days and 30% at one year90. Still, prognosis remains poor in HF and survival 
rates may have stagnated after the millennium. In Study I, one- and three-year survival of 
patients in NYHA class II-IV was around 80 and 55% respectively. There were no significant 
changes over time between 2003 and 2012. The lack of improvement in survival over 
time was probably related to the absence of increased utilization of existing and emerging 
treatments during the period. Our findings on survival were recently confirmed in a large 
HF cohort in general practice in the UK. A lack of improved survival was reported between 
1998 and 2012 and one-year survival was 81%91. In Study II and III with mainly patients in 
NYHA class III-IV, one-year mortality ranged from 61-81% depending on age and severity 
of disease. In Study II patients who received repetitive levosimendan treatment had higher 
survival rates than controls. It is emphasized however, that these were crude numbers without 
any adjustments, and the difference is likely due to selection bias and not treatment effect. 
The relative survival analysis in Study III indicates that in patients below 80 years of age, 
mortality was mainly related to HF and/or HF associated comorbidities.
HFpEF is believed to have slightly better survival than HFrEF19. In Study IV, 28- day and 
one-year mortality in hospitalized HFpEF was 11 and 34%, respectively. These findings 
are consistent with some studies on ADHF92,93, but higher than in others94. The relatively 
unselected and elderly population and high comorbidity burden in our data may partly 
explain the high mortality in our study.
 
Drug and device therapy in HFrEF
Pharmacological treatment with beta-blockers, RAS antagonists and MRA improve survival 
in HFrEF and strong recommendations from international guidelines support the use of these 
therapies in HFrEF4,95. The main findings in Study I were that the use of RAS antagonists 
and beta-blockers in Sweden was high and stable over time. The use of MRA decreased 
significantly from 53 to 42% risk-adjusted. Of note is that until the EMPHASIS-HF trial40 was 
published in 2011, MRA was indicated only in NYHA III-IV and 29 to 37% of the patients 
in our study were in NYHA class II. The use of device therapy was overall poor despite a 
trend towards increased implementation over a 10-year period. Considering that the study 
population had EF<30%, a duration of HF > 6 months, and >50% had QRS prolongation 
(≥120ms), the use of CRT and ICD was markedly below expected and appropriate. 
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Underutilization of treatments
Other registries and even active programs to improve implementation of evidence-based 
treatments also report underuse of MRA ranging from 36% to 60% among patients with 
appropriate indication96,97. Non-treatment may partly be explained by be intolerance and 
frequent MRA-related side effects. We found that 30% discontinued MRA treatment between 
first and last visit. After the publication of RALES, a Canadian analysis reported an increase 
hyperkalemia-related complications98. However, these findings were not confirmed in a 
longitudinal cohort analysis from Scotland where increased laboratory monitoring of the 
patients was observed parallel to increased prescription of MRA 99. This may indicate that 
severe side-effects can be minimized with proper monitoring and follow up. This may also 
be the reason why HF clinics appear to have similar rates of hyperkalemia to those observed 
in randomized trials100. 
Underutilization of device therapy has been reported previously101-103. Poor awareness 
and low referral rates amongst physicians are believed to be important causes of ICD 
underutilization104,105. A Swedish study from 2014 found this to be true both for ICD and 
CRT treatment106. The authors invited a random sample of Swedish physicians working 
in cardiology, internal medicine or family medicine, to fill in a survey on indications for 
device pharmaceutical therapy. Acceptable awareness was met by 32% for CRT and 15% 
for ICD treatment, and 37% stated that ICD is never indicated unless there is documentation 
of ventricular arrhythmias. Being a certified specialist in cardiology was the only significant 
predictor of reasonable awareness. In Study I we found a somewhat higher use of device 
therapy in patients seen by cardiologists and in centers that implant CRT and ICDs. LBBB is 
shown to be a predictor of mortality regardless of age and is more common with increasing 
age107. Additionally, in contrast to ICD, CRT treatment may be indicated for symptom relief, 
not only to improve prognosis4. Despite this, underutilization of CRT is more pronounced in 
the elderly107.
In contrast to unawareness of guideline recommendations, reasons for low implementation 
may also be due to lack of convincing evidence. Even though prophylactic ICD therapy has 
a class I indication in the guidelines, the evidence behind ICD treatment is not as robust 
as for drug therapy. There is a controversy about survival benefits in the elderly since they 
are often excluded from randomized trials108. The survival benefit for non-ischemic HF 
also remains debated. The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) is the 
only randomized trial including non-ischemic cardiomyopathy to show a survival benefit. 
A positive effect was only seen in the NYHA class II (not III) and no patients were treated 
with CRT50. The very recent Defibrillator Implantation in Patients with Nonischemic Systolic 
Heart Failure (DANISH) study from 2016, thus not affecting the interpretation of the results 
at time of publication of Study I, randomized 1,116 patients with non-ischemic HF to receive 
ICD or conventional therapy. The association with the primary endpoint of all-cause mortality 
was not significantly different between the groups52. The current study differed from previous 
trials in the comprehensive HF drug treatment and the 58% concomitant CRT therapy. These 
treatments collectively reduce mortality substantially and thus make it harder to prove an 
additional effect on all-cause mortality from ICD treatment, especially since the risk of non-
sudden and non-cardiovascular death increases with time109. In subgroup analysis, there was 
a significant survival benefit in the ICD arm for patients younger than 68 years of age. The 
implications of this study on future guidelines and treatment patterns is still unclear. 
Treatment of HF in the elderly remains a challenge. They have a high comorbidity burden, 
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treatment is complicated by multipharmacy and frailty. Furthermore, few randomized trials 
have focused on quality of life, a parameter that may have a higher priority in these patients 
than reduction in mortality. The elderly are also underrepresented in clinical trials, mean age 
in the large randomized HF trials that treatment guidelines are based upon is just over 60 
years and less than 30% of the participants are older than 70 years110. Registry based, real 
world data however, indicate reduction in mortality and hospitalization rates for guideline 
recommended evidence-based treatments even in the elderly111,112. Moreover, in Study III 
we showed that up to 80 years of age mortality in HFrEF patients was mainly HF related. 
Cognitive function, frailty and patient preference are important elements in the decision-
making in HF management in the elderly. These factors, commonly not captured in studies, 
may partly explain the underuse of HF treatments in our studies. Furthermore, it may be 
assumed that older patients with chronic disease prefer improved symptoms to prolonged 
survival. However, a study of end-of-life preferences in HF showed that the majority of 
the patients preferred longevity over quality of life and that prediction of preference was 
inaccurate113. Patient-centered management including an open dialogue about expectations, 
preferences and available treatments is important to provide optimal care in the elderly.
Levosimendan in heart failure
Inotropic drugs are used to stabilize patients with ADHF with compromised systemic perfusion 
and end-organ function. Evidence is conflicting, and treatment with inotropic agents has even 
been reported to be harmful73-75.  In Study II the relatively novel inotrope levosimendan 
was found to be the most frequently used inotrope in cardiology and internal  medicine in 
Sweden. At least 10% of hospitalizations with NYHA III-IV and EF<40% received inotropes, 
a surprisingly high number considering that only 4% of ADHF have cardiogenic shock8. 
A possible explanation for this is the extensive use of planned repetitive levosimendan 
treatment, 38% of all levosimendan registrations, that we report. It is interesting that this type 
of levosimendan treatment in the non-acute setting has become established in some hospitals 
in Sweden, despite the lack of convincing evidence. Possible explanations may be increasing 
patient demand or the physician’s wish to “do something” for a patient when no further 
treatment options exists, as well as a bridging strategy to maintain organ function while 
awaiting HTx. We found however, that 59% of the patients who received planned repetitive 
levosimendan did not have device therapy. Of these, 46 and 98% had indications for CRT 
and ICD respectively. To justify a treatment with limited evidence, prior optimization of 
guideline-recommended, evidence-based treatment should be performed. 
Referral to a heart failure center for potential advanced therapy
With progression of disease and symptoms despite optimal medical and device therapy, 
possible interventions are advanced therapies such as HTx and LVAD. Patients are however 
believed to be underserved with these treatments16,60. Organ shortage is limiting the number 
of possible HTx, whereas the reasons for underutilization of LVADs are unclear. Possible 
explanations include physician and patient skepticism and doubts regarding cost effectiveness 
and medical benefits, but the major reason is however most likely unawareness. For general 
practitioners or cardiologists who do not deal with advanced HF on a daily basis, it may be 
difficult to identify patients who may benefit from HTx or LVAD therapy. Furthermore, the 
speed of disease progression in HF is often unpredictable and optimal timing for potential 
LVAD implantation is hard to define16. Patients are often referred too late, when end-organ 
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failure that disqualify for treatment is already present16. Valuable prognostic tools in the patient 
selection process such as peak VO2, HFSS and SHFM are likely too complex for general 
practitioners16,62. In Study III, we propose that the comprehensive assessment of indications 
and contraindications for HTx and LVAD therapy should be performed in HF centers were 
knowledge and experience in this field is high. We introduce five simple risk factors and 
propose that the presence of at least one of these should prompt referral to a HF specialist. The 
five risk factors are systolic BP ≤90 mm Hg; creatinine ≤160 mmol/L; hemoglobin ≤120 g/L; 
no RAS antagonist; and no beta-blocker. These factors were prospectively selected because 
of their ability to independently predict mortality (based on previous literature, but confirmed 
in our data), and their simplicity and availability in daily practice. Additionally, when one or 
more of these risk factors become present, they reflect a change in the progression of disease 
and a change in prognosis, as opposed to risk factors such as ischemic etiology or sex. In 
patients <80 years of age, the presence of one risk factor indicate worse one-year survival 
than post HTx and post LVAD implantation114. 
What would the impact of these referral criteria be? In our study, 41% of the patients <80 
years of age fulfilled the proposed criteria for referral to a HF specialist. A referral for 
evaluation, by no means equals HTx or LVAD indication. As outlined above, the selection 
process is complex, and detailed assessment of indication, contraindications, patient 
preference and motivation needs to be performed to identify patients suitable for treatment. 
Furthermore, before referral for advanced therapy, patients should have optimal evidence-
based drug and device treatment. Both in Study I and Study II utilization of ICD and CRT 
was poor. If a patient does not receive guideline recommended treatment, evaluation by 
a HF specialist for optimization seems motivated. Intolerance to beta-blockers and RAS-
antagonists has repeatedly been shown to be a marker of poor prognosis in HF27. Whether 
the absence of treatment in our data is due to true intolerance or more reflects the treating 
physician’s perception of contraindications or limited monitoring possibilities is unclear. 
Regardless, both of these reasons motivate referral to a HF specialist. With the proposed 
referral criteria, many of the patients will be too sick and beyond possible advanced treatment 
options, especially those with several risk factors present. Apart from a high risk of death and 
frequent hospitalization admissions, these patients experience marked reduction in quality 
of life, and depression and anxiety is common115. A randomized controlled  trial recently 
published showed that palliative programs can reduce readmissions and improve symptoms 
in patients with end stage HF (ESHF)116. Palliative care is substantially less implemented in 
HF than in cancer, and it is often initiated too late117,118. A HF specialist may be better suited 
in identifying patients with ESHF than generalists, hence even for this patient group referral 
to a HF center is justified.  
HFpEF
The discussion of utilization of evidence-based treatments is limited to half of the HF 
population. For the other half, the patients with HFpEF, no evidence-based treatment is 
available. HFpEF remains a huge clinical challenge, and the prevalence is thought to be 
increasing with the aging population. In the search for treatments and treatment targets, a 
better understanding of the HFpEF population is needed. Furthermore, despite the absence 
of treatment options, it is still valuable to assess prognosis and identify high-risk patients in 
need for intensified in-hospital and early post-discharge monitoring.  In Study IV predictors 
of 28-day and one-year mortality were identified in patients hospitalized with ADHF and 
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preserved EF and a score for risk evaluation at hospital admission was created. Most identified 
predictors in our study confirmed findings from previous studies on ADHF regardless of 
EF119-121. Symptoms and signs as risk predictors are however, mostly not assessed in risk 
models. We found hypoxia at admission to be one of the four most powerful predictors of 
both short and intermediate-term mortality. To our knowledge this has not been described 
previously. Both low122 and high123 systolic BP have been found to be predictors of mortality 
in acute decompensated HFpEF. It has been hypothesized that patients presenting with ADHF 
and high BP vs. low BP differ in characteristics and possibly underlying pathophysiology. 
Those with high BP may be in early or mid-stage of the disease, and those with low BP in 
more advanced low output stage of the disease124 or with more severely impaired systolic 
contractility despite preserved EF. In HFpEF, hypertrophy, a small left ventricle and high 
filling pressures may contribute to a low output state122. We found lower systolic BP to be a 
predictor of one-year mortality and lower diastolic BP to be a predictor for 28-day mortality. 
The reason for this difference is unclear. In previous studies, diastolic BP has been a weaker 
predictor than systolic BP in acute settings124.
Risk score
Numerous risk scores have been developed for risk prediction and estimation of prognosis in 
HF out of which some have gained an important role in clinical decision-making, e. g. SHFM 
and HFSS for transplantation selection26,27. Important performance measures of a risk score 
include discrimination, i. e. the ability to separate those with and those without an outcome 
of interest, and calibration, i. e. how well predicted outcomes match observed outcomes. 
Furthermore, to prove the risk score’s generalizability, its performance should be validated in 
a different dataset from which it was derived. Our risk scores had good discrimination assessed 
by AUC and calibration assessed by Hosmer-Lemeshow statistics and plots of predicted vs. 
observed mortality. We performed validation of the risk scores in the latest addition to the 
dataset of hospitalizations from 2012, however, an important next step will be validation in 
a different cohort. A goal for the risk scores in Study IV was to use variables available in 
daily practice and to keep the scores as simple as possible. Hence, in the model building we 
removed variables despite statistical significance if their contribution to discrimination of the 
model was negligible. We ended up with 9 and 8 variables respectively in the risk scores for 
short- and intermediate-term mortality. A next step to facilitate the use of the risk scores will 
be to create a web-based calculator.
Ideally, a risk score should have some impact on treatment. We created a risk score for a 
population of patients were no evidence-based treatments exists. Risk prediction may still 
be of use to guide decisions regarding in-patient and early post-discharge care and to help 
patients and family to a better understanding of disease severity. Furthermore, a potential use 
may be in trial design for patient selection in ADHF and HFpEF.
Strengths and limitations of the datasets
Data in Study I-III are from SwedeHF, one of the world’s largest HF registries with more 
than 70,000 patients in total and around 9,000 patients registered annually. Since the 
registry was founded an increasing number of sites report to the registry and an increasing 
number of patients are registered annually. The registry is representative for HF hospital 
care in Sweden, given that 19 out of 21 counties and more than 60 of about 75 hospitals, 
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including both university hospitals and community hospitals, are represented in the registry. 
Possibly, participating centers as opposed to non-participating centers, are biased towards 
more academic interest and more HF focused cardiology departments, resulting in a more 
ambitious HF care. Capture of primary care centers is poor with only 10% of primary care 
centers reporting to the registry.
In Study II, we performed a validation of the “inotrope” variable in the registry. Of the 
registrations with inotropes “yes” that were validated, only 68% were confirmed with 
inotrope use (Figure 6, Study II). The 32% not-confirmed inotrope use were in the validation 
found to be incorrect recordings or patients had received other drugs that may have been 
interpreted as inotropes, e.g. digoxin. The Registry performs validation on selected variables 
at randomly chosen centers every year. The 32% of incorrect registrations that we found is 
a much higher number that what has been found for other variables.  Reasons for this may 
be that inotropes are often administered in the intensive care unit (ICU). The nurses that 
performed the validation may not have had access to ICU medical charts. Hence, inotropes 
were likely administered in many cases rather than incorrectly registered, but not confirmed 
in the medical records. Furthermore, validation was complicated by the fact that registrations 
went back to 2000, a time were drug treatment was not electronically documented.
In the community surveillance of the ARIC study (Study IV), medical records are abstracted 
by trained staff and hospitalizations are adjudicated as ADHF. The adjudication has been 
shown to have a higher sensitivity than simply using un-validated HF discharge codes in 
identifying ADHF hospitalizations125. The use of a stratified randomized sampling technique 
for the selection of hospitalizations and the participation of four diverse United States 
Communities in the Surveillance lead to generalizable and external valid findings. 
A limitation of the Surveillance is that unique patients cannot be identified. Analysis is 
based on hospitalizations and patients that are rehospitalized may reoccur in the dataset. 
However, with the use of sampling criteria for selection of hospitalizations, this possibility 
is minimized. With a mean sampling fraction of 0,213 and a prior hospitalization for HF 
documented in around 30% and not necessarily in the study period, a maximum of 6% of the 
hospitalizations could represent rehospitalizations of patients already captured in the dataset.
Future perspectives
As outlined above, the underutilization of evidence-based therapies seen in our studies 
seems to be a universal problem in the care for HF patients. Parallel to the search of novel 
treatments, existing evidence-based treatments must be implemented. New strategies are 
needed to increase awareness and reduce the gap between guideline-recommended therapy 
and actual provided therapy in clinical practice. Active programs and care initiatives such as 
“Get with the Guidelines” and the “Registry to Improve the Use of Evidence-Based Heart 
Failure Therapies in the Out-patient Setting” (IMPROVE-IT) have led to improvements in 
care91,126. In the IMPROVE-IT program, specific patient-level performance feedback to the 
treating cardiologist appeared to be of particular importance in order to improve conformity 
with guideline recommendations. SwedeHF has so far been only descriptive, without specific 
quality improvement mechanisms. Introduction of more quality controls and feedback from 
the registry to care givers would extend the scope of the registry and might motivate more 
centers to participate. The use of screening programs to identify patients for device therapy 
and advanced HF treatment may be effective and should be evaluated further64. A future 
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project, as a follow-up to Study III, would be to evaluate the use of the proposed criteria for 
referral to a HF specialist and the potential effect on utilization of treatments and identification 
of patients for advanced therapy. Although it would be desirable, it is currently not feasable 
to treat all HF patients in cardiology units. In Sweden, around half of the HF patients are 
followed mainly in primary care127. Better collaboration and shared care between the primary 
care physician and the cardiologist are needed. 
An aging population is well described in population demographic trends.  More studies and 
evidence on HFrEF treatments in the elderly are warranted.  With HFpEF being a disease of 
the elderly, prevalence will continue to increase. Studies must continue to characterize the 
HFpEF population and its phenotypes. With the heterogeneity of HFpEF, characterization of 
subgroups and identification of representative populations seem crucial in the search for new 
treatment options. 
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CONCLUSIONS
1) Mortality in HFrEF in Sweden remains high and has not changed over time. Evidence-
based treatment is underutilized in Sweden, in particular the use of device therapy.
2) Levosimendan is the dominant choice of inotrope in cardiology and internal medicine in 
Sweden. Effects of the frequent use of planned repetitive levosimendan treatment in a non-
acute setting needs to be evaluated further.
3) In patients with moderate to advanced HF, up to 80 years old, mortality is mainly related 
to HF and HF associated comorbidities. The use of few and simple risk factors as referral 
criteria to a HF center may increase the number of patients who can benefit from advanced 
therapies.
4) Age, BUN, hypoxia and low hemoglobin are strong predictors for 28-day and one-year 
mortality in patients hospitalized with acute HFpEF. The novel risk scores can provide 
estimates for mortality in these patients.
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